

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2019/071123 A1

(43) International Publication Date

11 April 2019 (11.04.2019)

(51) International Patent Classification:

A61K 45/00 (2006.01) A61P 35/00 (2006.01)

(74) Agent: ESPINO, Christine, G. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US).

(21) International Application Number:

PCT/US2018/054606

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:

05 October 2018 (05.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/569,239 06 October 2017 (06.10.2017) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(71) Applicant: TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US).

(72) Inventors: MIKULE, Keith, W.; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). WANG, Zebin; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). ZHOU, Yinghui; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US).

(54) Title: COMBINATION THERAPIES AND USES THEREOF




FIGURE 1

(57) **Abstract:** The present disclosure relates to combination therapies containing one or more PARP inhibitors and one or more angiogenesis inhibitor. Also described herein are therapeutic uses of such combination therapies for treating various disorders and conditions. The combination therapies and uses thereof can be useful for preventing tumor cell growth, preventing tumor metastasis, inducing an immune response or enhancing an immune response.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

COMBINATION THERAPIES AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims benefit of U.S. Provisional Application No. 62/569,239, filed October 6, 2017, which is hereby incorporated by reference in its entirety.

BACKGROUND

[0002] Niraparib is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor. Niraparib and pharmaceutically acceptable salts thereof, are disclosed in International Publication No. WO2007/113596 and European Patent No. EP2007733B1; International Publication No. WO2008/084261 and U.S. Patent No. 8,071,623; and International Publication No. WO2009/087381 and U.S. Patent No. 8,436,185. Methods of making niraparib and pharmaceutically acceptable salts thereof are disclosed in International Publication Nos. WO2014/088983 and WO2014/088984. Methods to treat cancer with niraparib and pharmaceutically acceptable salts thereof are disclosed in U.S. Provisional Patent Application Nos. 62/356,461 and 62/402,427. The contents of each of the foregoing references are incorporated herein by reference in their entirety.

[0003] Cancer is a serious public health problem, with about 595,690 people in the United States of America expected to die of cancer in 2016. Modern strategies for the development of novel cancer therapies include agents targeting specific molecular defects that characterize certain cancer cells in order to increase treatment efficacy and reduce toxicities. In breast cancer, targeted therapies have long been effective, as agents targeting hormone receptors in tumors expressing them and as antibodies or tyrosine kinase inhibitors targeting overexpressed or amplified HER2 molecules. Breast tumors expressing none of these are called triple-negative breast cancers (TNBC), which comprise about 15 % of breast cancers overall, about 70 % of breast cancers in individuals harboring a germline BRCA1 mutation, and 20 % in BRCA2 mutation carriers [1, 2, 3, 4]. The discovery of the family of nuclear enzymes poly [ADP-ribose] polymerases (PARPs) and their role in DNA-damage repair pathways opened the possibility of developing a new class of antineoplastic drugs with the ability to interfere with the DNA damage repair systems of cancer cells – PARP inhibitors.

SUMMARY

[0004] Provided herein is a method of treating a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

Also provided herein is a method of preventing a tumor cell growth in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor. Also provided herein is a method of preventing tumor metastasis in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor. Also provided herein is a method of inducing an immune response in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor. Also provided herein is a method of enhancing an immune response in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

[0005] In some embodiments, the first agent inhibits PARP1, or PARP2, or both.

[0006] In some embodiments, the first agent is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof.

[0007] In some embodiments, the first agent is a small molecule.

[0008] In some embodiments, the first agent is selected from the group consisting of: ABT-767, AZD 2461, BGB-290, BGP 15, CEP 8983, CEP 9722, DR 2313, E7016, E7449, fluzoparib (SHR 3162), IMP 4297, INO1001, JPI 289, JPI 547, monoclonal antibody B3-LysPE40 conjugate, MP 124, niraparib (ZEJULA) (MK-4827), NU 1025, NU 1064, NU 1076, NU1085, olaparib (AZD2281), ONO2231, PD 128763, R 503, R554, rucaparib (RUBRACA) (AG-014699, PF-01367338), SBP 101, SC 101914, Simmiparib, talazoparib (BMN-673), veliparib (ABT-888), WW 46, 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol, and salts or derivatives thereof.

[0009] In some embodiments, the first agent is selected from the group consisting of: niraparib, olaparib, rucaparib, talazoparib, veliparib, and salts or derivatives thereof.

[0010] In some embodiments, the first agent is niraparib or a pharmaceutically acceptable salt or derivative thereof.

[0011] In some embodiments, the angiogenesis inhibitor reduces the production of a pro-angiogenic factor, inhibits an interaction between a pro-angiogenic factor and a pro-angiogenic receptor, inhibits a function of a pro-angiogenic factor, inhibits a function of a pro-angiogenic factor receptor, reduces of blood flow by disruption of blood vessels, inhibits vessel sprouting, or any combinations thereof.

[0012] In some embodiments, the pro-angiogenic factor comprises FGF1-14, FGF15/19, FGF18-23, PDGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), Trimeresurus flavoviridis svVEGF, VEGFR-1, VEGFR-2, VEGFR-3, angiogenin, angiopoietin-1, angiopoietin-2, Tie-1, Tie-2, MMP, DII4, SEMA3s, ephrins, leptin, chemokines, transforming growth factor- β (TGF- β), or any combination thereof.

[0013] In some embodiments, the angiogenesis inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof.

[0014] In some embodiments, the angiogenesis inhibitor is selected from the group consisting of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor, matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, α V β 3 inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta, interferon alpha, soluble KDR and FLT-1 receptors, placental proliférin-related protein, pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, protamine, heparin, steroids, ascorbic acid ethers, sulfated polysaccharide DS 4152, fumagillin, AGM 12470, neovastat, RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), Flt2-11, CBO-P11, Je-11, V1, and any combination thereof.

[0015] In some embodiments, the angiogenesis inhibitor inhibits a DLL4/Notch signaling pathway.

[0016] In some embodiments, the angiogenesis inhibitor inhibiting the DLL4/Notch signaling pathway is a gamma-secretase inhibitor (GSI), a siRNA, or a monoclonal antibody against a Notch receptor or ligand.

[0017] In some embodiments, the angiogenesis inhibitor inhibiting a DLL4/Notch signaling pathway is selected from the group consisting of RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, and any combination thereof.

[0018] In some embodiments, the angiogenesis inhibitor inhibits a vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) pathway.

[0019] In some embodiments, the angiogenesis inhibitor is selected from the group consisting of Akt Inhibitor, calcineurin autoinhibitory peptide, ET-18-OCH₃, Go 6983, NG-Nitro-L-arginine methyl ester, p21-activated kinase Inhibitor, cPLA₂α inhibitor, PI-103, PP2, SB 203580, U0126, VEGFR tyrosine kinase inhibitor V, VEGFR2 kinase inhibitor VI, VEGFR2 kinase inhibitor III, ZM 336372, and any combination thereof.

[0020] In some embodiments, the angiogenesis inhibitor inhibits a VEGF family protein and/or a VEGFR family protein.

[0021] In some embodiments, the VEGF family protein comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), Trimeresurus flavoviridis svVEGF, or any combination thereof.

[0022] In some embodiments, the VEGFR family protein comprises VEGFR-1, VEGFR-2, VEGFR-3, or any combination thereof.

[0023] In some embodiments, the angiogenesis inhibitor comprises a VEGF inhibitor, a VEGFR inhibitor, or a combination thereof.

[0024] In some embodiments, the angiogenesis inhibitor induces homologous recombinant (HR) deficiency.

[0025] In some embodiments, the angiogenesis inhibitor induces hypoxia.

[0026] In some embodiments, the angiogenesis inhibitor induces homologous recombinant (HR) deficiency by hypoxia.

[0027] In some embodiments, the VEGF inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological

materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof.

- [0028] In some embodiments, the VEGF inhibitor is an antibody or a fragment thereof.
- [0029] In some embodiments, the VEGF inhibitor is bevacizumab, ranibizumab, OPT-302, ziv-aflibercept, or any combinations thereof.
- [0030] In some embodiments, the VEGF inhibitor is a small organic or inorganic molecule.
- [0031] In some embodiments, the small organic or inorganic molecule is Flt2-11, CBO-P11, Je-11, V1, or any combination thereof.
- [0032] In some embodiments, the VEGFR inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; a tyrosine kinase inhibitor; or any combination thereof.
- [0033] In some embodiments, the VEGFR inhibitor is a tyrosine kinase inhibitor.
- [0034] In some embodiments, the tyrosine kinase inhibitor is pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, or any combination thereof.
- [0035] In some embodiments, the VEGFR inhibitor is an antibody or a fragment thereof.
- [0036] In some embodiments, the VEGFR inhibitor is ramucirumab.
- [0037] In some embodiments, a first agent is niraparib, and a second agent is cabozantinib.
- [0038] In some embodiments, a first agent is niraparib, and a second agent is bevacizumab.
- [0039] In some embodiments, administering comprises administering the first and second agent sequentially.
- [0040] In some embodiments, administering comprises administering the first and second agent simultaneously.
- [0041] In some embodiments, administering comprises administering the first agent before administering the second agent.
- [0042] In some embodiments, administering comprises administering the second agent before administering the first agent.
- [0043] In some embodiments, the subject is a mammalian subject.
- [0044] In some embodiments, the subject is a mouse.
- [0045] In some embodiments, the subject is a human.
- [0046] In some embodiments, the disease or condition is cancer.

[0047] In some embodiments, the cancer is selected from the group consisting of carcinoma, squamous carcinoma, adenocarcinoma, sarcomata, endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, colon cancer, colorectal cancer, squamous cell carcinoma of the anogenital region, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, squamous cell carcinoma of the lung, stomach cancer, bladder cancer, gall bladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, glioblastoma, glioma, squamous cell carcinoma of the head and neck, prostate cancer, pancreatic cancer, mesothelioma, sarcoma, hematological cancer, leukemia, lymphoma, neuroma, and combinations thereof.

[0048] In some embodiments, the cancer is breast cancer.

[0049] In some embodiments, the breast cancer is triple negative breast cancer.

[0050] In some embodiments, the cancer is ovarian cancer.

[0051] In some embodiments, the cancer is colorectal cancer.

[0052] In some embodiments, a first agent is niraparib, and a second agent is cabozantinib.

[0053] In some embodiments, a first agent is niraparib, and a second agent is bevacizumab.

[0054] In some embodiments, administering the first agent, the second agent, or both comprises administering the first agent, the second agent, or both ocularly, oral, parenterally, topically, bronchially, buccally, intradermally, interdermally, transdermally, enterally, intra-arterially, intradermally, intragastrically, intramedullarily, intramuscular, intranasally, intraperitoneally, intrathecally, intravenously, intraventricularly, within a specific organ (e.g., intrahepatically), mucosally, nasally, orally, rectally, subcutaneously, sublingually, topically, tracheally, vaginally, vitreally, or any combination thereof.

[0055] In some embodiments, administering comprises administering a composition formulated for oral administration comprising the first agent.

[0056] In some embodiments, the composition is a capsule.

[0057] In some embodiments, the composition is a tablet.

[0058] In some embodiments, the composition (e.g., a capsule or tablet) further comprises one or more pharmaceutically acceptable excipients.

[0059] In some embodiments, the one or more pharmaceutically acceptable excipients comprises lactose monohydrate, magnesium stearate, or a combination thereof.

[0060] In some embodiments, a therapeutically effective amount of the first or second agent is administered.

[0061] In some embodiments, the subject has previously been treated with one or more different cancer treatment modalities.

[0062] In some embodiments, the subject has previously been treated with one or more of radiotherapy, chemotherapy, or immunotherapy.

[0063] In some embodiments, the subject has been treated with one, two, three, four, or five lines of prior therapy.

[0064] In some embodiments, the prior therapy is a cytotoxic therapy.

[0065] In some embodiments, the method further comprises administering a third agent to the subject, or performing a therapy on the subject selected from the group consisting of surgery, radiotherapy, or a combination thereof.

[0066] In some embodiments, the third agent comprises a radiotherapeutic agent, an anti-immunosuppressive agent or immunostimulatory agent, a chemotherapeutic agent, or a combination thereof.

[0067] In some embodiments, the anti-immunosuppressive agent or immunostimulatory agent comprises an anti-PD-1 agent, an anti-PD-L1 agent, an anti-CTLA4 agent, an anti-TIM-3 agent, an anti-LAG-3 agent, a GITR (glucocorticoid-induced TNFR-related protein) stimulating agent, an anti-IDO agent, an anti-ICOS agent, an anti-OX40 agent, an anti-CSF1R agent, a chemokine signaling agent, a cytokine signal stimulating agent, or any combination thereof.

[0068] In some embodiments, the anti-PD-1 agent is selected from the group consisting of pembrolizumab, nivolumab, PDR001, REGN2810 (SAR-439684), BGB-A317, BI 754091, IBI308, INC SHR-1210, JNJ-63723283, JS-001, MEDI0680 (AMP-514), MGA-012, PF-06801591, REGN-2810, TSR-042, atezolizumab, avelumab, CX-072, durvalumab, FAZ053, LY3300054, PD-L1 millamolecule, and any combinations thereof.

[0069] In some embodiments, the anti-PD-L1 agent is selected from the group consisting of atezolizumab, durvalumab, avelumab, LY3300054, and any combinations thereof.

[0070] In some embodiments, the GITR stimulating agent is selected from the group consisting of DTA-1, mGITRL, pGITRL, and any combinations thereof.

[0071] In some embodiments, the anti-CTLA4 agent is selected from the group consisting of ipilimumab, tremelimumab, and a combination thereof.

[0072] In some embodiments, the third agent is an anti-immunosuppressive agent or immunostimulatory agent selected from the group consisting of a flavonoid (e.g., flavonoid glycoside), lidocaine, lamotrigine, sulfamethoxazole, phenytoin, carbamazepine, sulfamethoxazole, phenytoin, allopurinol, paracetamol, mepivacaine, p-phenylenediamine, ciprofloxacin and moxifloxacin.

[0073] In some embodiments, the third agent is a chemotherapeutic agent selected from the group consisting of aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide,

bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, vinorelbine, and any combinations thereof.

[0074] In some embodiments, a therapeutically-effective amount of a therapeutic agent is administered to a subject. The therapeutic agent can be a first, a second, or a third agent. In some embodiments, the therapeutically-effective amount is from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 1 mg/kg/day, from 1 mg/kg/day to about 5 mg/kg/day, from 5 mg/kg/day to about 10 mg/kg/day, from 10 mg/kg/day to about 15 mg/kg/day, from 15 mg/kg/day to about 20 mg/kg/day, from 20 mg/kg/day to about 25 mg/kg/day, from 25 mg/kg/day to about 30 mg/kg/day, from 30 mg/kg/day to about 35 mg/kg/day, or from 35 mg/kg/day to about 40 mg/kg/day. In some embodiments, the therapeutically-effective amount is from 0.1 mg/kg/day to about 40 mg/kg/day. In some embodiments, the therapeutically-effective amount is from 10 mg/kg/day to about 50 mg/kg/day, or from 50 mg/kg/day to about 100 mg/kg/day.

[0075] In some embodiments, a first agent is administered at a dose that is equivalent to about 300 mg of niraparib. In some embodiments, the first agent is administered at a reduced dose. In some embodiments, the reduced dose is equivalent to 200 mg of niraparib. In some embodiments, the reduced dose is equivalent to 100 mg ~ 150 mg, or 150 mg ~200 mg of niraparib. In some embodiments, the first agent (e.g. niraparib) is administered at an increased dose if the subject's hemoglobin \geq 9 g/dL, platelets \geq 100,000/ μ L and neutrophils \geq 1500/ μ L for all labs performed during one or more treatment cycles. In some embodiments, the dose of the first agent (e.g. niraparib) is increased after two cycles of treatment.

[0076] Provided herein is a pharmaceutical composition comprising any of the first agents described herein and any of the second agents described herein. In some embodiments, the pharmaceutical composition further comprises any of the third agents described herein.

[0077] Provided herein is a kit comprising any of the first agents described herein and any of the second agents described herein. In some embodiments, the kit further comprises any of the third agents described herein.

INCORPORATION BY REFERENCE

[0078] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

[0079] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0080] **FIG. 1** depicts an exemplary study of niraparib and bevacizumab combination treatment in both ovarian and triple negative breast cancer (TNBC) models.

[0081] **FIG. 2** depicts an exemplary study of niraparib and cabozantinib combination treatment in both ovarian and TNBC models.

[0082] **FIG. 3A** depicts an exemplary study of tolerability and antitumor activity of niraparib and bevacizumab combination measured by mean tumor volume in ovarian cancer cell line-derived xenograft model A2780 (BRCA wt, homologous recombination deficiency negative (HRD-)).

[0083] **FIG. 3B** depicts an exemplary study of tolerability and antitumor activity of niraparib and bevacizumab combination measured by body weight in ovarian cancer cell line-derived xenograft model A2780 (BRCA wt, HRD-).

[0084] **FIG. 4A** depicts an exemplary study of tolerability and anti-tumor activity of niraparib and cabozantinib combination measured by mean tumor volume in ovarian cancer cell line-derived xenograft model A2780 (BRCA wt, HRD-).

[0085] **FIG. 4B** depicts an exemplary study of tolerability and anti-tumor activity of niraparib and cabozantinib combination measured by body weight in ovarian cancer cell line-derived xenograft model A2780 (BRCA wt, HRD-).

[0086] **FIG. 5** depicts an exemplary study of anti-tumor activity of niraparib and cabozantinib combination in ovarian patient-derived xenograft (PDX) model OVC134.

[0087] **FIG. 6A** depicts an exemplary study of anti-tumor activity of niraparib and bevacizumab combination in TNBC PDX model MAXF 574.

[0088] **FIG. 6B** depicts an exemplary study of anti-tumor activity of niraparib and cabozantinib combination in TNBC PDX model MAXF 574.

[0089] **FIG. 7A** depicts an exemplary study of anti-tumor activity of niraparib and bevacizumab combination in TNBC PDX model MAXF 857.

[0090] **FIG. 7B** depicts an exemplary study of anti-tumor activity of niraparib and cabozantinib combination in TNBC PDX model MAXF 857.

[0091] **FIG. 8A** depicts an exemplary study of anti-tumor activity of niraparib and bevacizumab combination in TNBC PDX model MAXF MX1.

[0092] **FIG. 8B** depicts an exemplary study of anti-tumor activity of niraparib and cabozantinib combination in TNBC PDX model MAXF MX1.

DETAILED DESCRIPTION

Definitions

[0093] The articles “a” and “an” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to include the plural referents. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process. Furthermore, it is to be understood that the invention encompasses all variations, combinations, and permutations in which one or more limitations, elements, clauses, descriptive terms, etc., from one or more of the listed claims is introduced into another claim dependent on the same base claim (or, as relevant, any other claim) unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise. Where elements are presented as lists, (e.g., in Markush group or similar format) it is to be understood that each subgroup of the elements is also disclosed, and any element(s) can be removed from the group. It should be understood that, in general, where the invention, or aspects of the invention, is/are referred to as comprising particular elements, features, etc., certain embodiments of the invention or aspects of the invention consist, or consist essentially of, such elements, features, etc. For purposes of simplicity those embodiments have not in every case been specifically set forth in so many words herein. It should also be understood that any embodiment or aspect of the invention can be explicitly excluded from the claims, regardless of whether the specific exclusion is recited in the

specification. The publications, websites and other reference materials referenced herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference.

[0094] As used herein, the term “administration” typically refers to the administration of a composition to a subject or system. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human subject. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time.

[0095] As used herein, the terms “dosage form” or “unit dosage form” refer to a physically discrete unit of an active agent (e.g., a therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (e.g., with a therapeutic regimen). Those of ordinary skill in the art appreciate that the total amount of a therapeutic composition or agent administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.

[0096] As used herein, the term “regimen” refers to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by one or more periods of time. In some embodiments, a given therapeutic agent is administered according to a regimen, which may involve one or more doses. In some embodiments, a regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some embodiments, a regimen comprises a plurality of doses, wherein the doses are separated by time periods of different length. In some embodiments, a regimen comprises doses of the same amount. In some

embodiments, a regimen comprises doses of different amounts. In some embodiments, a regimen comprises at least one dose, wherein the dose comprises one unit dose of the therapeutic agent. In some embodiments, a regimen comprises at least one dose, wherein the dose comprises two or more unit doses of the therapeutic agent.

[0097] As used herein, the term “effective amount” refers to the amount of a therapeutic agent disclosed herein which treats, upon single or multiple dose administration, a subject with a disease or condition. An effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount, the dose, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of the subject; its size, age, and general health; the specific condition, disorder, or disease involved; the degree of or involvement or the severity of the condition, disorder, or disease, the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances. An effective amount of the therapeutic agent disclosed herein is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 40 mg/kg/day. Specific amounts can be determined by the skilled person.

[0098] As used herein, the term “patient”, “subject”, or “test subject” refers to any organism, including a human or non-human, to which provided therapeutic agent or agents described herein are administered in accordance with the present disclosure e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, canines, felines, horses, cattle, pigs, deer, non-human primates, and humans; insects; worms; birds; reptiles; amphibians; etc.). In embodiments, the subject is a human. In some embodiments, the subject is a mouse. In some embodiments, a subject may be suffering from, and/or susceptible to a disease, disorder, and/or condition (e.g., cancer). In some embodiments, a patient is a human that has been diagnosed with a cancer. In some embodiments, a patient is a human possessing one or more female reproductive organs.

[0099] “Diluents” is a diluting agent and is also referred to as a filler, dilutant or thinner. “Diluents” increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling. Such compounds include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel[®]; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac[®] (Amstar);

mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose-based diluents, confectioner's sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like. Combinations of one or more diluents can also be used.

[00100] The term "excipient" means a pharmacologically inactive component such as a diluent, lubricant, surfactant, carrier, or the like. Excipients that are useful in preparing a pharmaceutical composition are generally safe, non-toxic and are acceptable for human pharmaceutical use. Reference to an excipient includes both one and more than one such excipient. Co-processed excipients are also covered under the scope of present disclosure.

[00101] "Filling agents" or "fillers" can refer to "diluents" and include compounds such as lactose, lactose monohydrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.

[00102] "Lubricants" and "glidants" are compounds that prevent, reduce or inhibit adhesion or friction of materials. Exemplary lubricants include, e.g., stearic acid, magnesium stearate, calcium hydroxide, talc, sodium stearyl fumarate, a hydrocarbon such as mineral oil, or hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex[®]), higher fatty acids and their alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, glycerol, talc, waxes, Stearowet[®], boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol (e.g., PEG-4000) or a methoxypolyethylene glycol such as CarbowaxTM, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica such as SyloidTM, Cab-O-Sil[®], a starch such as corn starch, silicone oil, a surfactant, and the like.

[00103] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66, 1–19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as

hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and $\text{N}^+(\text{C}_{1-4} \text{ alkyl})_4$ salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and aryl sulfonate.

[00104] As used herein, the term “antibody” refers to a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer specific binding to a particular target antigen. As is known in the art, intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a “Y-shaped” structure. Each heavy chain is comprised of at least four domains (each about 110 amino acids long) – an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CH1, CH2, and the carboxy-terminal CH3 (located at the base of the Y’s stem). A short region, known as the “switch”, connects the heavy chain variable and constant regions. The “hinge” connects CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region connect the two heavy chain polypeptides to one another in an intact antibody. Each light chain is comprised of two domains – an amino-terminal variable (VL) domain, followed by a carboxy-terminal constant (CL) domain, separated from one another by another “switch”. Those skilled in the art are well familiar with antibody structure and sequence elements, recognize “variable” and “constant” regions in provided sequences, and understand that there may be some flexibility in definition of a “boundary” between such domains such that different presentations of the same

antibody chain sequence may, for example, indicate such a boundary at a location that is shifted one or a few residues relative to a different presentation of the same antibody chain sequence. Intact antibody tetramers are comprised of two heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed. Naturally-produced antibodies are also glycosylated, typically on the CH2 domain. Each domain in a natural antibody has a structure characterized by an “immunoglobulin fold” formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as “complement determining regions” (CDR1, CDR2, and CDR3) and four somewhat invariant “framework” regions (FR1, FR2, FR3, and FR4). When natural antibodies fold, the FR regions form the beta sheets that provide the structural framework for the domains, and the CDR loop regions from both the heavy and light chains are brought together in three-dimensional space so that they create a single hypervariable antigen binding site located at the tip of the Y structure. The Fc region of naturally-occurring antibodies binds to elements of the complement system, and also to receptors on effector cells, including for example effector cells that mediate cytotoxicity. As is known in the art, affinity and/or other binding attributes of Fc regions for Fc receptors can be modulated through glycosylation or other modification. In some embodiments, antibodies produced and/or utilized in accordance with the present invention include glycosylated Fc domains, including Fc domains with modified or engineered such glycosylation. For purposes of the present invention, in certain embodiments, any polypeptide or complex of polypeptides that includes sufficient immunoglobulin domain sequences as found in natural antibodies can be referred to and/or used as an “antibody”, whether such polypeptide is naturally produced (e.g., generated by an organism reacting to an antigen), or produced by recombinant engineering, chemical synthesis, or other artificial system or methodology. In some embodiments, an antibody is polyclonal; in some embodiments, an antibody is monoclonal. In some embodiments, an antibody has constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, antibody sequence elements are humanized, primatized, chimeric, etc., as is known in the art. Moreover, the term “antibody” as used herein, can refer in appropriate embodiments (unless otherwise stated or clear from context) to any of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, embodiments, an antibody utilized in accordance with the present invention is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies[®], etc); antibody

fragments such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd' fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies[®]); Small Modular ImmunoPharmaceuticals ("SMIPsTM"); single chain or Tandem diabodies (TandAb[®]); VHHS; Anticalins[®]; Nanobodies[®] minibodies; BiTE[®]s; ankyrin repeat proteins or DARPINS[®]; Avimers[®]; DARTs; TCR-like antibodies; Adnectins[®]; Affilins[®]; Trans-bodies[®]; Affibodies[®]; TrimerX[®]; MicroProteins; Fynomers[®], Centryrins[®]; and KALBITOR[®]s. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc], or other pendant group [e.g., poly-ethylene glycol, etc.]).

[00105] As used herein, the term "antibody agent" refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses any polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient to confer specific binding. Exemplary antibody agents include, but are not limited to monoclonal antibodies or polyclonal antibodies. In some embodiments, an antibody agent may include one or more constant region sequences that are characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, an antibody agent may include one or more sequence elements are humanized, primatized, chimeric, etc., as is known in the art. In many embodiments, the term "antibody agent" is used to refer to one or more of the art-known or developed constructs or formats for utilizing antibody structural and functional features in alternative presentation. For example, an antibody agent utilized in accordance with the present disclosure is in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies[®], etc); antibody fragments such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd' fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies[®]); Small Modular ImmunoPharmaceuticals ("SMIPsTM"); single chain or Tandem diabodies (TandAb[®]); VHHS; Anticalins[®]; Nanobodies[®] minibodies; BiTE[®]s; ankyrin repeat proteins or DARPINS[®]; Avimers[®]; DARTs; TCR-like antibodies; Adnectins[®]; Affilins[®]; Trans-bodies[®]; Affibodies[®]; TrimerX[®]; MicroProteins; Fynomers[®], Centryrins[®]; and KALBITOR[®]s. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent

modification (e.g., attachment of a glycan, a payload [e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc.], or other pendant group [e.g., poly-ethylene glycol, etc.]). In many embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and/or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments, an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR. In some embodiments, an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments, an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments, an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments, an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments, an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin-binding domain.

[00106] As used herein, the term “combination therapy” refers to a clinical intervention in which a subject is exposed to two or more therapeutic regimens (e.g., two or more therapeutic

agents). In some embodiments, the two or more therapeutic regimens may be administered simultaneously. In some embodiments, the two or more therapeutic regimens may be administered sequentially (e.g., a first regimen administered prior to administration of any doses of a second regimen). In some embodiments, the two or more therapeutic regimens are administered in overlapping dosing regimens. In some embodiments, administration of combination therapy may involve administration of one or more therapeutic agents or modalities to a subject receiving the other agent(s) or modality. In some embodiments, combination therapy does not necessarily require that individual agents be administered together in a single composition (or even necessarily at the same time). In some embodiments, two or more therapeutic agents or modalities of a combination therapy are administered to a subject separately, e.g., in separate compositions, via separate administration routes (e.g., one agent orally and another agent intravenously), and/or at different time points. In some embodiments, two or more therapeutic agents may be administered together in a combination composition, or even in a combination compound (e.g., as part of a single chemical complex or covalent entity), via the same administration route, and/or at the same time.

[00107] As used herein, the term “angiogenesis” means any growth of blood vessels or any neo- or re-vascularization of a tissue. The growth may or may not be stimulated by cytokines, such as cytokine-mediated activation of blood vessel endothelial cells.

[00108] As used herein, the terms “metastasis” and “metastases” refer to the movement of a tumor cell from its primary site by any means or by any route, including local invasion, lymphatic spread, vascular spread or transcoelomic spread.

[00109] The terms “enhance” or “enhancing” refers to an increase or prolongation of either the potency or duration of a desired effect of a composition described herein, or a diminution of any adverse symptomatology that is consequent upon the administration of the therapeutic agent or agents. Thus, in regard to enhancing the effect of niraparib disclosed herein, the term “enhancing” refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents that are used in combination with niraparib disclosed herein. An “enhancing-effective amount,” as used herein, refers to an amount of niraparib or other therapeutic agent which is adequate to enhance the effect of another therapeutic agent or niraparib in a desired system. When used in a patient, amounts effective for this use will depend on the severity and course of the disease, disorder or condition, previous therapy, the patient’s health status and response to the drugs, and the judgment of the treating physician.

Overview

[00110] The present disclosure provides a combination therapy for a disease such as cancer. In the case of cancer therapy, the amalgamation of anti-cancer drugs can enhance efficacy compared to the monotherapy approach because it can target key pathways in a characteristically synergistic or an additive manner. This approach can potentially reduce drug resistance, while simultaneously providing therapeutic anti-cancer benefits, such as reducing tumor growth and metastatic potential, arresting mitotically active cells, reducing cancer stem cell populations, and inducing apoptosis.

[00111] The present disclosure provides combination therapies of PARP inhibitors and angiogenesis inhibitors. This combination benefit may be related to angiogenesis inhibitor-mediated conditional genetic instability. For example, angiogenesis inhibition can induce hypoxia, which could in turn downregulate homologous recombinant (HR) repair genes such as RAD51 and BRCA1. In addition, acute hypoxia and reoxygenation can induce both single strand and double strand DNA break within tumor cells as a result of increased levels of reactive oxygen species (ROS). Therefore, when cells are under hypoxic stress exerted by angiogenesis inhibitors, increased DNA damage and deficiency of the HR repair pathway may lead to heightened sensitivity to PARP inhibitors.

[00112] Provided herein is a method of treating a subject with a disease or condition, comprising administering to the subject a first agent and a second agent. Also provided herein is a method of preventing tumor cell growth in a subject with a disease or condition, comprising administering to the subject a first agent and a second agent. Further, provided herein is a method of preventing tumor metastasis in a subject with a disease or condition, comprising administering to the subject a first agent and a second agent. In a fourth aspect, provided herein is a method of inducing an immune response in a subject with a disease or condition comprising administering to the subject a first agent and a second agent. In a fifth aspect, provided herein is a method of enhancing an immune response in a subject with a disease or condition comprising administering to the subject a first agent and a second agent.

[00113] In various embodiments, the first agent provided herein inhibits poly [ADP-ribose] polymerase (PARP). In some cases, the first agent is selected from the group consisting of: niraparib, olaparib, rucaparib, talazoparib, and veliparib, or salts or derivatives thereof. In various embodiments, the second agent provided herein comprises an angiogenesis inhibitor. In some cases, the angiogenesis inhibitor can reduce the production of a pro-angiogenic factor, inhibit an interaction between a pro-angiogenic factor and a pro-angiogenic receptor, inhibit a function of a pro-angiogenic factor, and/or inhibit a function of a pro-angiogenic factor receptor.

In some cases, the angiogenesis inhibitor is selected from the group consisting of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor, matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, α V β 3 inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta, interferon alpha, soluble KDR and FLT-1 receptors, placental proliferin-related protein, pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, protamine, heparin, steroids, ascorbic acid ethers, sulfated polysaccharide DS 4152, fumagillin, AGM 12470, neovastat, RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), Flt2-11, CBO-P11, Je-11, V1, and any combination thereof.

[00114] In some embodiments, the methods further comprise administering a third agent.

[00115] Also provided herein is a pharmaceutical composition comprising the first and second agent disclosed herein. In some embodiments, the pharmaceutical composition further comprises the third agent. Also provided herein is a kit comprising the first and the second agent disclosed herein. In some embodiments, the kit further comprises the third agent.

Indications

[00116] In some embodiments, the disease or condition that can be treated with the methods disclosed herein is cancer. Cancer is an abnormal growth of cells which tend to proliferate in an uncontrolled way and, in some cases, to metastasize (spread). Cancer is not one disease. It is a group of more than 100 different and distinctive diseases. Cancer can involve any tissue of the body and have many different forms in each body area. Most cancers are named for the type of cell or organ in which they start. A tumor can be cancerous or benign. A benign tumor means the tumor can grow but does not spread. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. If a cancer spreads (metastasizes), the new tumor bears the same name as the original (primary) tumor. The frequency of a particular cancer may depend on gender. While skin cancer is the most common type of malignancy for both men and women, the second most common type in men is prostate cancer and in women, breast cancer.

[00117] The methods of the disclosure can be used to treat any type of cancer known in the art. Non-limiting examples of cancers to be treated by the methods of the present disclosure can include melanoma (e.g., metastatic malignant melanoma), renal cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone refractory prostate adenocarcinoma), pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer (e.g., non-small cell lung cancer), esophageal cancer, squamous cell carcinoma of the head and neck, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, glioma, leukemia, lymphoma, and other neoplastic malignancies. Additionally, the disease or condition provided herein includes refractory or recurrent malignancies whose growth may be inhibited using the methods of the invention. In some embodiments, a cancer to be treated by the methods of the present disclosure is selected from the group consisting of carcinoma, squamous carcinoma, adenocarcinoma, sarcomata, endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, colon cancer, colorectal cancer, squamous cell carcinoma of the anogenital region, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, squamous cell carcinoma of the lung, stomach cancer, bladder cancer, gall bladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, glioblastoma, glioma, squamous cell carcinoma of the head and neck, prostate cancer, pancreatic cancer, mesothelioma, sarcoma, hematological cancer, leukemia, lymphoma, neuroma, and combinations thereof. In some embodiments, a cancer to be treated by the methods of the present disclosure include, for example, carcinoma, squamous carcinoma (for example, cervical canal, eyelid, tunica conjunctiva, vagina, lung, oral cavity, skin, urinary bladder, tongue, larynx, and gullet), and adenocarcinoma (for example, prostate, small intestine, endometrium, cervical canal, large intestine, lung, pancreas, gullet, rectum, uterus, stomach, mammary gland, and ovary). In some embodiments, a cancer to be treated by the methods of the present disclosure further include sarcomata (for example, myogenic sarcoma), leukosis, neuroma, melanoma, and lymphoma. In some embodiments, a cancer to be treated by the methods of the present disclosure is breast cancer. In some embodiments, a cancer to be treated by the methods of the present disclosure is triple negative breast cancer (TNBC). In some embodiments, a cancer to be treated by the methods of the present disclosure is ovarian cancer. In some embodiments, a cancer to be treated by the methods of the present disclosure is colorectal cancer.

[00118] In some embodiments, a patient or population of patients to be treated with combination therapy of the present disclosure have a solid tumor. In some embodiments, a solid tumor is a melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gall bladder cancer, laryngeal cancer, liver cancer, thyroid cancer, stomach

cancer, salivary gland cancer, prostate cancer, pancreatic cancer, or Merkel cell carcinoma. In some embodiments, a patient or population of patients to be treated with combination therapy of the present disclosure have a hematological cancer. In some embodiments, the patient has a hematological cancer such as Diffuse large B cell lymphoma (“DLBCL”), Hodgkin’s lymphoma (“HL”), Non-Hodgkin’s lymphoma (“NHL”), Follicular lymphoma (“FL”), acute myeloid leukemia (“AML”), or Multiple myeloma (“MM”).

[00119] Specific examples of cancers that can be prevented and/or treated in accordance with present disclosure include, but are not limited to, the following: renal cancer, kidney cancer, glioblastoma multiforme, metastatic breast cancer; breast carcinoma; breast sarcoma; neurofibroma; neurofibromatosis; pediatric tumors; neuroblastoma; malignant melanoma; carcinomas of the epidermis; leukemias such as but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome, chronic leukemias such as but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as but not limited to Hodgkin’s disease, non-Hodgkin’s disease; multiple myelomas such as but not limited to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom’s macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone cancer and connective tissue sarcomas such as but not limited to bone sarcoma, myeloma bone disease, multiple myeloma, cholesteatoma-induced bone osteosarcoma, Paget’s disease of bone, osteosarcoma, chondrosarcoma, Ewing’s sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi’s sarcoma, leiomyosarcoma, liposarcoma, lymphangio sarcoma, neurilemmoma, rhabdomyosarcoma, and synovial sarcoma; brain tumors such as but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendrolioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and primary brain lymphoma; breast cancer including but not limited to adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget’s disease (including juvenile Paget’s disease) and inflammatory breast cancer; adrenal cancer such as but not limited to pheochromocytom and adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer such as but not limited to, insulinoma, gastrinoma,

glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers such as but limited to Cushing's disease, prolactin-secreting tumor, acromegaly, and diabetes insipidus; eye cancers such as but not limited to ocular melanoma such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; vaginal cancers such as squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer such as squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers such as but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers such as but not limited to endometrial carcinoma and uterine sarcoma; ovarian cancers such as but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; cervical carcinoma; esophageal cancers such as but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers such as but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; colorectal cancer, KRAS mutated colorectal cancer; colon carcinoma; rectal cancers; liver cancers such as but not limited to hepatocellular carcinoma and hepatoblastoma, gallbladder cancers such as adenocarcinoma; cholangiocarcinomas such as but not limited to papillary, nodular, and diffuse; lung cancers such as KRAS-mutated non-small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; lung carcinoma; testicular cancers such as but not limited to germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers such as but not limited to, androgen-independent prostate cancer, androgen-dependent prostate cancer, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancers; oral cancers such as but not limited to squamous cell carcinoma; basal cancers; salivary gland cancers such as but not limited to adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers such as but not limited to squamous cell cancer, and verrucous; skin cancers such as but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers such as but not limited to renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and/or uterine); renal carcinoma; Wilms' tumor; bladder cancers such as but not limited to transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancers include

myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangioendotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas.

[00120] In embodiments, a cancer is breast cancer, ovarian cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, prostate cancer, testicular cancer, pancreatic cancer, esophageal cancer, head and neck cancer, gastric cancer, bladder cancer, lung cancer (e.g., adenocarcinoma, NSCLC and SCLC), bone cancer (e.g., osteosarcoma), colon cancer, rectal cancer, thyroid cancer, brain and central nervous system cancers, glioblastoma, neuroblastoma, neuroendocrine cancer, rhabdoid cancer, keratoacanthoma, epidermoid carcinoma, seminoma, melanoma, sarcoma (e.g., liposarcoma), bladder cancer, liver cancer (e.g., hepatocellular carcinoma), kidney cancer (e.g., renal cell carcinoma), myeloid disorders (e.g., AML, CML, myelodysplastic syndrome and promyelocytic leukemia), and lymphoid disorders (e.g., leukemia, multiple myeloma, mantle cell lymphoma, ALL, CLL, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma) may be treated with compounds and methods described herein.

[00121] In some embodiments, a cancer is a gynecologic cancer (e.g., breast cancer or a cancer of the female reproductive system such as ovarian cancer, fallopian tube cancer, cervical cancer, vaginal cancer, vulvar cancer, uterine cancer, or primary peritoneal cancer). In some embodiments, cancers of the female reproductive system include, but are not limited to, ovarian cancer, cancer of the fallopian tube(s), peritoneal cancer, and breast cancer.

[00122] In embodiments, a cancer is an ovarian cancer. The term 'ovarian cancer' is often used to describe epithelial cancers that begin in the ovary, in the fallopian tube, and from the lining of the abdominal cavity, call the peritoneum. In embodiments, a cancer is epithelial ovarian cancer. In embodiments, a cancer is fallopian tube cancer. In embodiments, a cancer is primary peritoneal cancer.

[00123] In embodiments, a cancer is a breast cancer. Breast cancer is the second most common cancer in the world with approximately 1.7 million new cases in 2012 and the fifth most common cause of death from cancer, with approximately 521,000 deaths. Of these cases, approximately 15% are triple-negative, which do not express the estrogen receptor, progesterone receptor (PR) or HER2. In some embodiments, triple negative breast cancer (TNBC) is characterized as breast cancer cells that are estrogen receptor expression negative (<1% of cells), progesterone receptor expression negative (<1% of cells), and HER2-negative. In embodiments,

a breast cancer is associated with homologous recombination repair deficiency/homologous repair deficiency (“HRD”).

Role of poly [ADP-ribose] polymerases (PARPs)

[00124] Poly [ADP-ribose] polymerases (PARPs) are a family of enzymes that cleave NAD⁺, releasing nicotinamide, and successively add ADP-ribose units to form ADP-ribose polymers. Accordingly, activation of PARP enzymes can lead to depletion of cellular NAD⁺ levels (e.g., PARPs as NAD⁺ consumers) and mediates cellular signaling through ADP-ribosylation of downstream targets. PARP-1 is a zinc-finger DNA-binding enzyme that is activated by binding to DNA double or single strand breaks. It was known that anti-alkylating agents could deplete the NAD⁺ content of tumor cells, and the discovery of PARPs explained this phenomenon. Anti-alkylating agents induce DNA strand breaks, which activates PARP-1, which is a part of the DNA repair pathway. Poly ADP-ribosylation of nuclear proteins by PARP-1 converts DNA damage into intracellular signals that can either activate DNA repair (e.g., by the base excision repair (BER) pathway); or trigger cell death in the presence of DNA damage that is too extensive and cannot be efficiently repaired.

[00125] PARP-2 contains a catalytic domain and is capable of catalyzing a poly(ADP-ribosyl)ation reaction. PARP-2 can display auto-modification properties similar to PARP-1. The protein is localized in the nucleus *in vivo* and may account for the residual poly [ADP-ribose] synthesis observed in PARP-1-deficient cells, treated with alkylating agents or hydrogen peroxide. Some agents that inhibit PARP (e.g., agents primarily aimed at inhibiting PARP-1) may also inhibit PARP-2 (e.g., niraparib).

[00126] The role of PARP enzymes in DNA damage response (e.g., repair of DNA in response to genotoxic stress) has led to the compelling suggestion that PARP inhibitors may be useful anti-cancer agents. PARP inhibitors may be particularly effective in treating cancers resulting from germ line or sporadic deficiency in the homologous recombination DNA repair pathway, such as BRCA-1 and/or BRCA-2 deficient cancers.

[00127] Pre-clinical *ex vivo* and *in vivo* experiments suggest that PARP inhibitors are selectively cytotoxic for tumors with homozygous inactivation of BRCA-1 and/or BRCA-2 genes, which are known to be important in the homologous recombination (HR) DNA repair pathway. The biological basis for the use of PARP inhibitors as single agents in cancers with defects in BRCA-1 and/or BRCA-2 can be the requirement of PARP-1 and PARP-2 for base excision repair (BER) of the damaged DNA. Upon formation of single-strand DNA breaks, PARP-1 and PARP-2 can bind at sites of lesions, become activated, and catalyze the addition of long polymers of ADP-ribose (PAR chains) on several proteins associated with chromatin,

including histones, PARP itself, and various DNA repair proteins. This can result in chromatin relaxation and fast recruitment of DNA repair factors that access and repair DNA breaks. Normal cells can repair up to 10,000 DNA defects daily and single strand breaks can be the most common form of DNA damage. Cells with defects in the BER pathway can enter S phase with unrepaired single strand breaks. Pre-existing single strand breaks can be converted to double strand breaks as the replication machinery passes through the break. Double strand breaks present during S phase may be repaired by the error-free HR pathway. Cells with inactivation of genes required for HR, such as BRCA-1 and/or BRCA-2, accumulate stalled replication forks during S phase and may use error-prone non-homologous end joining (NHEJ) to repair damaged DNA. Both the inability to complete S phase (because of stalled replication forks) and error-prone repair by NHEJ, can contribute to cell death.

[00128] Treatment with PARP inhibitors may selectively kill a subset of cancer cells with deficiencies in DNA repair pathways (e.g., inactivation of BRCA-1 and/or BRCA-2). For example, a tumor arising in a patient with a germline BRCA mutation can have a defective homologous recombination DNA repair pathway and would be increasingly dependent on BER, a pathway blocked by PARP inhibitors, for maintenance of genomic integrity. This mechanism of inducing death by use of PARP inhibitors to block one DNA repair pathway in tumors with pre-existing deficiencies in a complementary DNA repair pathways is referred to as synthetic lethality.

[00129] The therapeutic potential of PARP inhibitors is further expanded by the observation that PARP inhibitors not only have monotherapy activity in HR-deficient tumors, but are also effective in preclinical models in combination with other agents such as cisplatin, carboplatin, alkylating and methylating agents, radiation therapy, and topoisomerase I inhibitors. In contrast to the rationale for monotherapy in which PARP inhibition alone is sufficient for cell death in HR-deficient cancers (due to endogenous DNA damage), PARP may be required for repair of DNA damage induced by standard cytotoxic chemotherapy. In some cases, PARP may be required to release trapped topoisomerase I/irinotecan complexes from DNA. Temozolomide-induced DNA damage can be repaired by the BER pathway, which may require PARP to recruit repair proteins. Combination therapies that enhance or synergize the cancer therapy without significantly increasing toxicity can provide substantial benefit to cancer patients, including ovarian cancer patients.

PARP Inhibitors

[00130] PARP inhibitors can have activity against tumors with existing DNA repair defects, such as BRCA1 and BRCA2. Treatment with PARP inhibitors (e.g., PARP-1/2 inhibitors) may

selectively kill a subset of cancer cell types by exploiting their deficiencies in DNA repair. Human cancers exhibit genomic instability and an increased mutation rate due to underlying defects in DNA repair. These deficiencies can render cancer cells more dependent on the remaining DNA repair pathways and targeting these pathways can have a much greater impact on the survival of the tumor cells than on normal cells.

[00131] In some embodiments, agents that inhibit PARP include agents that inhibit PARP-1 and/or PARP-2. In some embodiments, agent that inhibits PARP is selected from the group consisting of ABT-767, AZD 2461, BGB-290, BGP 15, CEP 9722, E7016, E7449, fluzoparib, INO1001, JPI 289, MP 124, niraparib, olaparib, ONO2231, rucaparib, SC 101914, talazoparib, veliparib, WW 46, and salts or derivatives thereof. In some embodiments, a PARP inhibitor is niraparib, olaparib, rucaparib, talazoparib, veliparib, or any combination thereof. In some embodiments, agent that inhibits PARP is selected from the group consisting of ABT-767, AZD 2461, BGB-290, BGP 15, CEP 8983, CEP 9722, DR 2313, E7016, E7449, fluzoparib (SHR 3162), IMP 4297, INO1001, JPI 289, JPI 547, monoclonal antibody B3-LysPE40 conjugate, MP 124, niraparib (ZEJULA) (MK-4827), NU 1025, NU 1064, NU 1076, NU1085, olaparib (AZD2281), ONO2231, PD 128763, R 503, R554, rucaparib (RUBRACA) (AG-014699, PF-01367338), SBP 101, SC 101914, Simmiparib, talazoparib (BMN-673), veliparib (ABT-888), WW 46, 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol, and salts or derivatives thereof. In some embodiments, a PARP inhibitor can be prepared as a pharmaceutically acceptable salt. In some embodiments, an agent that inhibits PARP is niraparib or a salt or derivative thereof. One of skill in the art will appreciate that such salt forms can exist as solvated or hydrated polymorphic forms.


[00132] In one aspect, pharmaceutical compositions provided herein in various embodiments comprise a PARP inhibitor and a second agent. In some embodiments, the second agent is an angiogenesis inhibitor. In some embodiments, the angiogenesis inhibitor inhibits VEGF/VEGFR pathway. In some embodiments, the angiogenesis inhibitor is a VEGF and/or VEGFR inhibitor. In another aspect, methods provided herein comprise administering a PARP inhibitor and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

Niraparib

[00133] Niraparib is an orally active and potent poly [ADP-ribose] polymerase (PARP) inhibitor. Niraparib and pharmaceutically acceptable salts thereof, are disclosed in International Publication No. WO2007/113596 and European Patent No. EP2007733B1; International Publication No. WO2008/084261 and U.S. Patent No. 8,071,623; and International Publication No. WO2009/087381 and U.S. Patent No. 8,436,185. Methods of making niraparib and

pharmaceutically acceptable salts thereof are disclosed in International Publication Nos. WO2014/088983 and WO2014/088984. Methods to treat cancer with niraparib and pharmaceutically acceptable salts thereof are disclosed in U.S. Provisional Patent Application Nos. 62/356,461 and 62/402,427. The contents of each of the foregoing references are incorporated herein by reference in their entirety.

[00134] In some embodiments, the present invention relates to use of niraparib in combination with one or more additional pharmaceutically active agents affecting activity within the tumor microenvironment. Niraparib, (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine, is an orally available, potent, poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP)-1 and -2 inhibitor. Niraparib has the following structure:



[00135] The empirical molecular formula for niraparib is C₂₆H₃₀N₄O₅S and its molecular weight is 510.61. Niraparib tosylate monohydrate drug substance is a white to off-white, non-hygroscopic crystalline solid. Niraparib solubility is pH independent below the pKa of 9.95, with an aqueous free base solubility of 0.7 mg/mL to 1.1 mg/mL across the physiological pH range. See WO 2008/084261 (published on July 17, 2008) and WO 2009/087381 (published July 16, 2009), the entirety of each of which is hereby incorporated by reference. Niraparib can be prepared according to Scheme 1 of WO 2008/084261. As used herein, the term “niraparib” can mean any of the free base compound ((3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine), a salt form, including pharmaceutically acceptable salts, of (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine (e.g., (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine tosylate), or a solvated or hydrated form thereof (e.g., (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine tosylate monohydrate). In some embodiments, such forms may be individually referred to as “niraparib free base”, “niraparib tosylate” and “niraparib tosylate monohydrate”, respectively. Unless otherwise specified, the term “niraparib” includes all forms of the compound (3S)-3-[4-{7-(aminocarbonyl)-2H-indazol-2-yl}phenyl]piperidine.

[00136] In some embodiments, niraparib can be prepared as a pharmaceutically acceptable salt. One of skill in the art will appreciate that such salt forms can exist as solvated or hydrated polymorphic forms. In some embodiments, niraparib is prepared in the form of a hydrate.

[00137] In certain embodiments, niraparib is prepared in the form of a tosylate salt. In some embodiments, niraparib is prepared in the form of a tosylate monohydrate.

[00138] The crystalline tosylate monohydrate salt of niraparib is being developed as a monotherapy agent for tumors with defects in the homologous recombination (HR) deoxyribonucleic acid (DNA) repair pathway and as a sensitizing agent in combination with cytotoxic agents and radiotherapy.

[00139] Provided herein are compositions containing niraparib or its pharmaceutically acceptable salts. The compositions may further include one or more additional active ingredients which impact efficacy of niraparib.

[00140] In some embodiments, the niraparib is a pharmaceutically acceptable salt of niraparib. In some embodiments, the pharmaceutically acceptable salt is niraparib tosylate monohydrate.

[00141] The formulation can comprise one or more components, including niraparib. The components can be combined to create granules that are then compressed to form tablets.

[00142] The niraparib may be present in the formulation as a pharmaceutically acceptable salt. For example, the niraparib can be niraparib tosylate monohydrate.

[00143] The niraparib formulations described herein can be administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, and other factors known to medical practitioners. In human therapy, the dosage forms described herein deliver niraparib formulations that maintain a therapeutically effective amount of niraparib in plasma while reducing the side effects associated with an elevated C_{max} blood plasma level of niraparib.

Pharmaceutically acceptable salts

[00144] In some embodiments, the niraparib used in a composition disclosed herein is the form of a free base, pharmaceutically acceptable salt, prodrug, analog or complex. In some instances, the niraparib comprises the form of a pharmaceutically acceptable salt. In some embodiments, with respect to niraparib in a composition, a pharmaceutically acceptable salt includes, but is not limited to, 4-methylbenzenesulfonate salts, sulfate salts, benzenesulfate salts, fumarate salts, succinate salts, and stereoisomers or tautomers thereof. In some embodiments, with respect to niraparib in a composition, a pharmaceutically acceptable salt includes, but is not limited to, tosylate salts. In some embodiments, with respect to niraparib in a composition, a pharmaceutically acceptable salt includes, but is not limited to, tosylate monohydrate salts.

Additional pharmaceutically acceptable excipients

[00145] In some aspects, the pharmaceutical composition disclosed herein further comprises one or more pharmaceutically acceptable excipients. In some embodiments, the one or more pharmaceutically acceptable excipient is present in an amount of about 0.1-99 % by weight. Exemplary pharmaceutically acceptable excipients for the purposes of pharmaceutical compositions disclosed herein include, but are not limited to, binders, disintegrants, superdisintegrants, lubricants, diluents, fillers, flavors, glidants, sorbents, solubilizers, chelating agents, emulsifiers, thickening agents, dispersants, stabilizers, suspending agents, adsorbents, granulating agents, preservatives, buffers, coloring agents and sweeteners or combinations thereof. Examples of binders include microcrystalline cellulose, hydroxypropyl methylcellulose, carboxyvinyl polymer, polyvinylpyrrolidone, polyvinylpolypyrrolidone, carboxymethylcellulose calcium, carboxymethylcellulose sodium, ceratonia, chitosan, cottonseed oil, dextrates, dextrin, ethylcellulose, gelatin, glucose, glyceryl behenate, galactomannan polysaccharide, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, inulin, lactose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer, polycarbophil, polydextrose, polyethylene glycol, polyethylene oxide, polymethacrylates, sodium alginate, sorbitol, starch, sucrose, sunflower oil, vegetable oil, tocofersolan, zein, or combinations thereof. Examples of disintegrants include hydroxypropyl methylcellulose (HPMC), low substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium, sodium starch glycolate, lactose, magnesium aluminum silicate, methylcellulose, polacrilin potassium, sodium alginate, starch, or combinations thereof. Examples of a lubricant include stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, glycerin monostearate, glyceryl palmitostearate, magnesium lauryl sulfate, mineral oil, palmitic acid, myristic acid, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, sodium lauryl sulfate, talc, zinc stearate, potassium benzoate, magnesium stearate or combinations thereof. Examples of diluents include talc, ammonium alginate, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, cellulose, cellulose acetate, corn starch, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, glyceryl palmitostearate, isomalt, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, microcrystalline cellulose, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sulfobutylether β -cyclodextrin, tragacanth, trehalose, xylitol, or combinations thereof. In some embodiments, the pharmaceutically acceptable excipient is hydroxypropyl methylcellulose (HPMC). In some embodiments, the pharmaceutically acceptable excipient is low substituted hydroxypropyl cellulose (L-HPC). In some embodiments, the pharmaceutically acceptable

excipient is lactose. In some embodiments, the pharmaceutically acceptable excipient is lactose monohydrate. In some embodiments, the pharmaceutically acceptable excipient is magnesium stearate. In some embodiments, the pharmaceutically acceptable excipient is lactose monohydrate and magnesium stearate.

[00146] Various useful fillers or diluents include, but are not limited to calcium carbonate (BarcroftTM, MagGranTM, MillicarbTM, Pharma- CarbTM, PrecarbTM, SturcalTM, Vivapres CaTM), calcium phosphate, dibasic anhydrous (Emcompress AnhydrousTM, FujicalinTM), calcium phosphate, dibasic dihydrate (CalstarTM, Di-CafosTM, EmcompressTM), calcium phosphate tribasic (Tri-CafosTM, TRI- TABTM), calcium sulphate (DestabTM, DrieriteTM, Snow WhiteTM, Cal-TabTM, CompactrolTM), cellulose powdered (ArbocelTM, ElcemaTM, SanacetTM), silicified microcrystalline cellulose, cellulose acetate, compressible sugar (Di- PacTM), confectioner's sugar, dextrates (CandexTM, EmdexTM), dextrin (AvedexTM, CaloreenTM, Primogran WTM), dextrose (CaridexTM, DextrofinTM, Tab fine D-IOOTM), fructose (FructofinTM, KrystarTM), kaolin (LionTM, Sim 90TM), lactitol (Finlac DCTTM, Finlac MCXTM), lactose (AnhydroxTM, CapsuLacTM, Fast-FloTM, FlowLacTM, GranuLacTM, InhaLacTM, LactochemTM, LactohaieTM, LactopressTM, MicrofmeTM, MicrotoseTM, PharmatoseTM, Prisma LacTM, RespitoseTM, SacheLacTM, SorboLacTM, Super-TabTM, TablettoseTM, WyndaleTM, ZeparoxTM), lactose monohydrate, magnesium carbonate, magnesium oxide (MagGran MOTTM), maltodextrin (C*Dry MDTM, Lycatab DSHTTM, MaldexTM, MaitagranTM, MaltrinTM, Maltrin QDTM, Paselli MD 10 PHTM, Star-DriTM), maltose (Advantose 100TM), mannitol (MannogemTM, PearlitolTM), microcrystalline cellulose (Avicel PHTTM, CelexTM, CelphereTM, Ceolus KGTM, EmcocelTM, PharmacelTM, TabuloseTM, VivapurTM), polydextrose (LitesseTM), simethicone (Dow Corning Q7- 2243 LVATM, Cow Coming Q7- 2587TM, Sentry SimethiconeTM), sodium alginate (KeltoneTM, ProtanalTM), sodium chloride (AlbergerTM), sorbitol (Liponec 70-NCTTM, Liponic 76-NCv, MeritolTM, NeosorbTM, Sorbitol InstantTM, SorbogemTM), starch (Flufiex WTM, Instant Pure-CoteTM, MelojeiTM, Meritena Paygel 55TM, Perfectamyl D6PHTM, Pure- CoteTM, Pure-DentTM, Pure-GelTM, Pure-SetTM, Purity 21TM, Purity 826TM, Tablet WhiteTM), pregelatinized starch, sucrose, trehalose and xylitol, or mixtures thereof.

[00147] Various useful disintegrants include, but are not limited to, alginic acid (ProtacidTM, Satialgine H8TM), calcium phosphate, tribasic (TRI-TABTM), carboxymethylcellulose calcium (ECG 505TM), carboxymethylcellulose sodium (AkucellTM, FinnfixTM, Nymcel Tylose CBTM), colloidal silicon dioxide (AerosilTM, Cab-O-SilTM, Wacker HDKTM), croscarmellose sodium (Ac-Di-SolTM, Pharmacel XLTM, PrimelloseTM, SolutabTM, VivasolTM), crospovidone (Collison CLTM, Collison CL-MTM, Polyplasdone XLTM), docusate sodium, guar gum (MeyprodorTM,

MeyprofmTM, MeyproguarTM), low substituted hydroxypropyl cellulose, magnesium aluminum silicate (MagnabiteTM, NeusilinTM, PharmisorbTM, VeegumTM), methylcellulose (MethocelTM, MetoloseTM), microcrystalline cellulose (Avicel PHTM, Ceoius KGTM, EmcoelTM, EthispheresTM, FibrocelTM, PharmacelTM, VivapurTM), povidone (CollisonTM, PlasdomeTM) sodium alginate (KelcosolTM, KetoneTM, ProtanalTM), sodium starch glycolate, polacrilin potassium (Amberlite IRP88TM), silicified microcrystalline cellulose (ProSotvTM), starch (Aytex PTM, Fluftex WTM, MelojetTM, MeritenaTM, Paygel 55TM, Perfectamyl D6PHTM, Pure-BindTM, Pure-CoteTM, Pure-DentTM, Purity 21TM, Purity 826TM, Tablet WhiteTM) or pre- gelatinized starch (Lycatab PGTM, MerigelTM, National 78-1551TM, Pharma-GelTM, PrejelTM, Sepistab ST 200TM, Spress B820TM, Starch 1500 GTM, TablitzTM, Unipure LDTM), or mixtures thereof.

[00148] Various useful lubricants include, but are not limited to, calcium stearate (HyQualTM), glycerine monostearate (ImwitorTM 191 and 900, Kessco GMS5TM, 450 and 600, Myvaplex 600PTM, MyvatexTM, Rita GMTM, Stepan GMTM, TeginTM, TeginTM 503 and 515, Tegin 4100TM, Tegin MTM, Unimate GMTM), glyceryl behenate (Compritol 888 ATOTM), glyceryl palmitostearate (Precirol ATO 5TM), hydrogenated castor oil (Castorwax MP 80TM, CroduretTM, Cutina HRTM, FancolTM, Simulsol 1293TM), hydrogenated vegetable oil 0 type I (SterotexTM, Dynasan P60TM, HydrocoteTM, Lipovol HS-KTM, Sterotex HMTTM), magnesium lauryl sulphate, magnesium stearate, medium-chain triglycerides (Captex 300TM, Labrafac CCTM, Miglyol 810TM, Neobee M5TM, NesatolTM, Waglinol 3/9280TM), poloxamer (PluronicTM, SynperonicTM), polyethylene 5 glycol (Carbowax SentryTM, LipoTM, LipoxolTM, Lutrol ETM, Pluriol ETM), sodium benzoate (AntimolTM), sodium chloride, sodium lauryl sulphate (Elfan 240TM, Texapon K1 2PTM), sodium stearyl fumarate (PruvTM), stearic acid (HystreneTM, IndustreneTM, Kortacid 1895TM, PristereneTM), talc (AltaicTM, LuzenacTM, Luzenac PharmaTM, Magsil OsmanthusTM, 0 Magsil StarTM, SuperioreTM), sucrose stearate (Surfhope SE Pharma D-1803 FTM) and zinc stearate (HyQualTM) or mixtures thereof. Examples of suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, glyceryl behenate, polyethylene glycol, polyethylene oxide polymers, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, DL-leucine, colloidal silica, and others as known in the art. In some embodiments a lubricant is magnesium stearate.

[00149] Various useful glidants include, but are not limited to, tribasic calcium phosphate (TRI- TABTM), calcium silicate, cellulose, powdered (SanacelTM, Solka- FloeTM), colloidal silicon dioxide (AerosilTM, Cab-O-Sil M-5PTM, Wacker HDKTM), magnesium silicate, magnesium trisilicate, starch (MelojetTM, MeritenaTM, Paygel 55TM, Perfectamyl D6PHTM, Pure-BindTM, Pure-CoteTM, Pure-DentTM, Pure-GelTM, Pure-SetTM, Purity 21TM, Purity 826TM, Tablet

WhiteTM) and talc (Luzenac PharmaTM, Magsil OsmanthusTM, Magsil StarTM, SuperioreTM), or mixtures thereof.

[00150] Pharmaceutically acceptable surfactants include, but are limited to both non-ionic and ionic surfactants suitable for use in pharmaceutical dosage forms. Ionic surfactants may include one or more of anionic, cationic or zwitterionic surfactants. Various useful surfactants include, but are not limited to, sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of olyoxyethylene sorbitane, sodium dioctylsulfosuccinate (DOSS), lecithin, stearic alcohol, cetostearyl alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or any other commercially available co-processed surfactant like SEPITRAP[®] 80 or SEPITRAP[®] 4000 and mixtures thereof.

Angiogenesis

[00151] Angiogenesis refers to the generation of new blood vessels into a tissue or organ. Under normal physiological conditions, humans or animals only undergo angiogenesis in very specific restricted situations. For example, angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum, endometrium and placenta. The control of angiogenesis is a highly regulated system of pro-angiogenic factors and anti-angiogenic factors.

[00152] The control of angiogenesis can be altered in certain disease states and, in many cases, the pathological damage associated with the disease is related to uncontrolled angiogenesis. Both controlled and uncontrolled angiogenesis can proceed in a similar manner. Endothelial cells and pericytes, surrounded by a basement membrane, can form capillary blood vessels. Angiogenesis can begin with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes. The endothelial cells, which line the lumen of blood vessels, then protrude through the basement membrane. Angiogenic stimulants, such as pro-angiogenic factors, induce the endothelial cells to migrate through the eroded basement membrane. The migrating cells form a “sprout” off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate. This process can refer to “vessel sprouting”. The endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system. The angiogenesis signaling pathway can primarily be regulated through tyrosine kinase receptors, therefore, the controlling mechanisms of angiogenesis can be the paracrine regulation of tyrosine kinase receptors, primarily on endothelial cells.

[00153] Pro-angiogenic factors can include fibroblast growth factors (FGF) and vascular endothelial growth factors (VEGF) which function as endothelial cell mitogens. Besides FGFs

and VEGFs, the VEGF receptors (VEGF-R1, -R2 and -R3), and placental growth factors (PlGF) are also pro-angiogenic factors. In addition, several factors, such as the angiopoietins, ephrins, leptin and chemokines, can play a role in angiogenesis.

[00154] The fibroblast growth factor (FGF) family with its prototype members FGF-1 (acidic FGF, or aFGF) and FGF-2 (basic FGF, or bFGF) consists of at least 22 known members, including FGF1-14, FGF15/19 (FGF15 is the mouse ortholog of human FGF19, and there is no human FGF15), FGF18-23. Most are single-chain peptides of 16-18 kDa and display high affinity to heparin and heparan sulfate. In general, FGFs can stimulate a variety of cellular functions by binding to cell surface FGF-receptors in the presence of heparin proteoglycans. The FGF-receptor family is composed of seven members, and all the receptor proteins are single-chain receptor tyrosine kinases that become activated through autophosphorylation induced by a mechanism of FGF-mediated receptor dimerization. Receptor activation can give rise to a signal transduction cascade that leads to gene activation and diverse biological responses, including cell differentiation, proliferation, and matrix dissolution, thus initiating a process of mitogenic activity critical for the growth of endothelial cells, fibroblasts, and smooth muscle cells. FGF-1, unique among all 22 members of the FGF family, can bind to all seven FGF-receptor subtypes, making it the broadest-acting member of the FGF family, and a potent mitogen for the diverse cell types needed to mount an angiogenic response in damaged (hypoxic) tissues, where upregulation of FGF-receptors occurs. FGF-1 stimulates the proliferation and differentiation of all cell types necessary for building an arterial vessel, including endothelial cells and smooth muscle cells; this fact distinguishes FGF-1 from other pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF), which primarily drives the formation of new capillaries.

[00155] Vascular endothelial growth factor (VEGF) can be another contributor to angiogenesis, increasing the number of capillaries in a given network. Initial in vitro studies demonstrated bovine capillary endothelial cells can proliferate and show signs of tube structures upon stimulation by VEGF and bFGF. In vitro studies have demonstrated that VEGF can be a potent stimulator of angiogenesis because, in the presence of this growth factor, plated endothelial cells will proliferate and migrate, eventually forming tube structures resembling capillaries. VEGF can cause a massive signaling cascade in endothelial cells. Binding to VEGF receptor-2 (VEGFR-2) can start a tyrosine kinase signaling cascade that stimulates the production of factors that variously stimulate vessel permeability (eNOS, producing NO), proliferation/survival (bFGF), migration (ICAMs/VCAMs/MMPs) and finally differentiation into mature blood vessels. Mechanically, VEGF can be upregulated with muscle contractions as a

result of increased blood flow to affected areas. The increased flow can also cause a large increase in the mRNA production of VEGF receptors 1 and 2. The increase in receptor production indicates that muscle contractions could cause upregulation of the signaling cascade relating to angiogenesis. As part of the angiogenic signaling cascade, NO can be a contributor to the angiogenic response because inhibition of NO can reduce the effects of pro-angiogenic growth factors.

[00156] The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) can play roles not only in physiological but also in most pathological angiogenesis, such as cancer. VEGF belongs to the platelet-derived growth factor (PDGF) supergene family characterized by 8 conserved cysteines and functions as a homodimer structure. VEGF family protein can include VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF. VEGF-A can regulate angiogenesis and vascular permeability by activating 2 receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk1 in mice). On the other hand, VEGF-C/VEGF-D and their receptor, VEGFR-3 (Flt-4), may mainly regulate lymphangiogenesis. The VEGF family includes other variants, one of which is the virally encoded VEGF-E and another is specifically expressed in the venom of the habu snake (*Trimeresurus flavoviridis*). VEGFRs are distantly related to the PDGFR family; however, they are unique with respect to their structure and signaling system. Unlike members of the PDGFR family that can stimulate the PI3K-Akt pathway toward cell proliferation, VEGFR-2, the signal transducer for angiogenesis, may utilize the PLC γ -PKC-MAPK pathway for signaling. The VEGF-VEGFR system can be targeted for anti-angiogenic therapy in cancer and can also be targeted for pro-angiogenic therapy in the treatment of neuronal degeneration and ischemic diseases.

[00157] Notch signaling can be involved in tumor pathologic angiogenesis. Whole transcriptome sequencing revealed that Hey1, a Notch target, can play a fundamental role in neoplastic vasculature development. Inhibition of Notch signaling can decrease the production of new blood vessels. Notch1 in connection with VEGF-A can have a significant prognostic impact, indicating that Notch pathway can increase the possibility of metastasis and poor outcome through regulating tumor angiogenesis via crosstalk with VEGF-A in cancer such as lung cancer. Blockade of the DLL4-Notch pathway may be associated with decreased angiogenesis and tumor growth. Combined targeting treatments of DLL4 and vascular endothelial growth factor (VEGF) signaling pathway can result in enhanced tumor growth inhibition and a marked decrease in tumor perfusion. Targeting Notch signaling may benefit patients with cancer.

[00158] Other pro-angiogenic factors include angiogenin, angiopoietins (Ang1 and Ang2), angiopoietin receptors Tie-1 and Tie-2, matrix metalloproteinase (MMP), delta-like ligand (DII4), Class 3 Semaphorins (SEMA3s), ephrins, leptin, transforming growth factor- β , and chemokines.

[00159] In some embodiments, the methods provided herein comprise administering a PARP inhibitor and an angiogenesis inhibitor. In some embodiments, the pharmaceutical compositions or kits provided herein comprise a PARP inhibitor and an angiogenesis inhibitor. In some embodiments, the angiogenesis inhibitor inhibits a pro-angiogenic factor, wherein the pro-angiogenic factor comprises FGF1-14, FGF15/19, FGF18-23, PDGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF, VEGFR-1, VEGFR-2, VEGFR-3, angiogenin, angiopoietin-1, angiopoietin-2, Tie-1, Tie-2, MMP, DII4, SEMA3s, ephrins, leptin, chemokines, transforming growth factor- β (TGF- β) or any combination thereof.

Angiogenesis inhibition

[00160] Persistent, unregulated angiogenesis can occur in a multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells and can support the pathological damage seen in these conditions. The diverse pathological states created due to unregulated angiogenesis have been grouped together as angiogenic dependent or angiogenic associated diseases. Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.

[00161] Tumor cells release various pro-angiogenic factors (e.g., angiogenin, vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and transforming growth factor- β (TGF- β). These can stimulate endothelial cell proliferation, migration and invasion resulting in new vascular structures sprouting from nearby blood vessels. Cell adhesion molecules, such as integrins, can be critical to the attachment and migration of endothelial cells to the extracellular matrix.

[00162] Tumor growth and metastasis depend on new growth in the vascular network supporting the tumor. VEGF can be secreted by tumor cells and act on endothelial cells to stimulate angiogenesis during tumor growth. Angiogenesis inhibitors such as VEGF inhibitors (e.g., bevacizumab) can increase numbers of antigen-specific T cells in solid tumors and enhance the efficiency of immunotherapy. For example, combination treatment of bevacizumab with either atezolizumab (inhibiting PD-L1) or ipilimumab (inhibiting CTLA-4) increases the number of intratumoral CD8 $^{+}$ cells. Other examples of VEGF inhibitors which may activate antigen-specific T cells in tumor microenvironments include pazopanib, sunitinib, sorafenib,

axitinib, ponatinib, regorafenib, cabozantinib, vandetanib, ramucirumab, lenvatinib and *ziv*-afiblercept.

[00163] Angiogenesis can be prominent in solid tumor formation and metastasis. Angiogenic factors have been found associated with several solid tumors such as rhabdomyosarcomas, retinoblastoma, Ewing's sarcoma, neuroblastoma, and osteosarcoma. A tumor cannot expand without a blood supply to provide nutrients and remove cellular wastes. Tumors in which angiogenesis may be important include solid tumors, and benign tumors such as acoustic neuroma, neurofibroma, trachoma and pyogenic granulomas. Prevention of angiogenesis could halt the growth of these tumors and the resultant damage to the animal due to the presence of the tumor.

[00164] Angiogenesis can be associated with blood-borne tumors such as leukemias, any of various acute or chronic neoplastic diseases of the bone marrow in which unrestrained proliferation of white blood cells occurs, usually accompanied by anemia, impaired blood clotting, and enlargement of the lymph nodes, liver, and spleen. Angiogenesis can play a role in the abnormalities in the bone marrow that give rise to leukemia-like tumors.

[00165] Angiogenesis may be important in two stages of tumor metastasis. The first stage can be in the vascularization of the tumor which allows tumor cells to enter the blood stream and to circulate throughout the body. After the tumor cells have left the primary site, and have settled into the secondary, metastasis site, angiogenesis occurs before the new tumor can grow and expand. Therefore, prevention of angiogenesis could lead to the prevention of metastasis of tumors and possibly contain the neoplastic growth at the primary site.

[00166] Angiogenesis can be a prognostic indicator for breast cancer. The amount of neovascularization found in the primary tumor can be determined by counting the microvessel density in the area of the most intense neovascularization in invasive breast carcinoma. A high level of microvessel density can correlate with tumor recurrence. Control of angiogenesis by therapeutic means could possibly lead to cessation of the recurrence of the tumors.

[00167] Angiogenesis can also be involved in normal physiological processes such as reproduction and wound healing. Angiogenesis may be an important step in ovulation and also in implantation of the blastula after fertilization. Prevention of angiogenesis could be used to induce amenorrhea, to block ovulation or to prevent implantation by the blastula. In wound healing, excessive repair or fibroplasia can be a detrimental side effect of surgical procedures and may be caused or exacerbated by angiogenesis. Adhesions can be a frequent complication of surgery and lead to problems such as small bowel obstruction.

[00168] Various compounds can be used to prevent angiogenesis. For example, angiogenesis inhibitors can include protamine, heparin and steroids. Steroids, such as tetrahydrocortisol, which lack gluco and mineral corticoid activity, can inhibit angiogenesis.

[00169] Other factors found endogenously in animals, such as a 4 kDa glycoprotein from bovine vitreous humor and a cartilage derived factor, can be used to inhibit angiogenesis. Cellular factors such as interferon can inhibit angiogenesis. For example, interferon α or human interferon β can inhibit tumor-induced angiogenesis in mouse dermis stimulated by human neoplastic cells. Human recombinant interferon (alpha/A) can also inhibit angiogenesis.

[00170] Other agents which can be used to inhibit angiogenesis include ascorbic acid ethers and related compounds. Sulfated polysaccharide DS 4152 can also show angiogenic inhibition. A fungal product, fumagillin, can be a potent angiostatic agent in vitro. The compound is toxic in vivo, but a synthetic derivative, AGM 12470, can be used in vivo to treat collagen II arthritis. Fumagillin and O-substituted fumagillin derivatives are disclosed in EPO Publication Nos. 0325199A2 and 0357061A1.

[00171] Angiogenesis inhibitors may reduce the production of a pro-angiogenic factor, inhibit an interaction between a pro-angiogenic factor and a pro-angiogenic receptor, inhibit a function of a pro-angiogenic factor, inhibit a function of a pro-angiogenic factor receptor, reduce of blood flow by disruption of blood vessels, or inhibit vessel sprouting. Angiogenesis inhibitors can target a VEGF/VEGFR pathway, or a DLL4/Notch signaling pathway.

[00172] In some embodiments, the methods provided herein comprise administering a PARP inhibitor and an angiogenesis inhibitor. In some embodiments, the angiogenesis inhibitor reduces the production of a pro-angiogenic factor, inhibits an interaction between a pro-angiogenic factor and a pro-angiogenic receptor, inhibits a function of a pro-angiogenic factor, inhibits a function of a pro-angiogenic factor receptor, reduces of blood flow by disruption of blood vessels, inhibits vessel sprouting, or any combinations thereof. In some embodiments, the angiogenesis inhibitor is selected from the group consisting of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor (e.g. peptide troponin I and chondromodulin I), matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, $\alpha\beta\beta$ inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta, interferon alpha, interferon beta, soluble KDR and FLT-1 receptors, placental proliferin-related protein, pazopanib, sunitinib,

sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, protamine, heparin, steroids, ascorbic acid ethers, sulfated polysaccharide DS 4152, fumagillin, AGM 12470, neovastat, RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), Flt₂₋₁₁, CBO-P11, Je-11, V1, and any combination thereof.

[00173] In some embodiments, the angiogenesis inhibitor induces homologous recombinant (HR) deficiency. In some embodiments, the angiogenesis inhibitor induces hypoxia. In some embodiments, the angiogenesis inhibitor induces homologous recombinant (HR) deficiency by hypoxia. In some embodiments, the angiogenesis inhibitor comprises a VEGF inhibitor, a VEGFR inhibitor, or a combination thereof.

[00174] In some embodiments, the PARP inhibitors of the present disclosure can be used in combination with an agent that inhibits a DLL4/Notch signaling pathway. In some embodiments, the agent inhibiting a DLL4/Notch signaling pathway is a gamma-secretase inhibitor (GSI), a siRNA, or a monoclonal antibody against a Notch receptor or ligand. In some embodiments, the agent inhibiting a DLL4/Notch signaling pathway is selected from the group consisting of RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), and any combination thereof.

[00175] In some embodiments, the PARP inhibitors of the present disclosure can be used in combination with an agent that inhibits a VEGF/VEGFR pathway. In some embodiments, the agent inhibits a VEGF family protein or a VEGFR family protein. In some embodiments, the agent inhibits VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF, or any combination thereof. In some embodiments, the agent inhibits VEGFR-1, VEGFR-2, VEGFR-3, or any combination thereof.

[00176] In some embodiment, the PARP inhibitors of the present disclosure can be used in combination with a VEGF inhibitor or a VEGFR inhibitor such as anti-VEGF antibodies, VEGF variants, soluble VEGF receptor fragments, aptamers capable of blocking VEGF or VEGFR, neutralizing anti-VEGFR antibodies, inhibitors of VEGFR tyrosine kinases and any combinations thereof (e.g., anti-hVEGF antibody A4.6.1, bevacizumab or ranibizumab). In some embodiments, the VEGF inhibitor or the VEGFR inhibitor is a small organic or inorganic molecule. In some embodiments, the VEGF inhibitor or the VEGFR inhibitor is an antibody or a

fragment thereof. In some embodiments, the VEGFR inhibitor is a tyrosine kinase inhibitor. In some embodiments, the VEGF inhibitor or VEGFR inhibitor is selected from the group consisting of bevacizumab, ranibizumab, OPT-302, ziv-aflibercept, pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, ramucirumab, Flt₂₋₁₁, CBO-P11, Je-11, V1, and any combination thereof.

Therapeutic agents

[00177] Therapeutic agents disclosed herein can be a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a protein fragment; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment; a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; or a toxin. In some embodiments, the therapeutic agent is a small organic or inorganic molecule. In some embodiments, the therapeutic agent is an antibody or a fragment thereof.

[00178] In various embodiments, the methods or compositions provided herein comprise a first agent and a second agent. In some embodiments, the first agent is a PARP inhibitor. In some embodiments, the first agent inhibits PARP1, PARP2, or both. In some embodiments, the first agent is selected from the group consisting of ABT-767, AZD 2461, BGB-290, BGP 15, CEP 8983, CEP 9722, DR 2313, E7016, E7449, fluzoparib (SHR 3162), IMP 4297, INO1001, JPI 289, JPI 547, monoclonal antibody B3-LysPE40 conjugate, MP 124, niraparib (ZEJULA) (MK-4827), NU 1025, NU 1064, NU 1076, NU1085, olaparib (AZD2281), ONO2231, PD 128763, R 503, R554, rucaparib (RUBRACA) (AG-014699, PF-01367338), SBP 101, SC 101914, Simmiparib, talazoparib (BMN-673), veliparib (ABT-888), WW 46, 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol, and salts or derivatives thereof. In some embodiments, the first agent is niraparib, or salts or derivatives thereof. In some embodiments, the second agent is an angiogenesis inhibitor. In some embodiments, the second agent is an angiogenesis inhibitor, wherein the angiogenesis inhibitor is selected from the group consisting of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor, matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, α V β 3 inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta,

interferon alpha, soluble KDR and FLT-1 receptors, placental proliferin-related protein, pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, protamine, heparin, steroids, ascorbic acid ethers, sulfated polysaccharide DS 4152, fumagillin, AGM 12470, neovastat, RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), Flt2-11, CBO-P11, Je-11, V1, and any combination thereof. In some embodiments, the second agent is an angiogenesis inhibitor, wherein the angiogenesis inhibitor inhibits a VEGF/VEGFR pathway. In some embodiments, the second agent is a VEGF inhibitor. In some embodiments, the second agent is a VEGFR inhibitor. In some embodiments, the angiogenesis inhibitor inhibits a DLL4/Notch signaling pathway.

[00179] In some embodiments, the methods and compositions disclosed herein further comprise a third agent. In some embodiments, the third agent comprises an anti-immunosuppressive agent or immunostimulatory agent, a chemotherapeutic agent, or a combination thereof. In some embodiments, the anti-immunosuppressive agent or immunostimulatory agent comprises an anti-PD-1 agent, an anti-PD-L1 agent, an anti-CTLA4 agent, an anti-TIM-3 agent, an anti-LAG-3 agent, a GITR (glucocorticoid-induced TNFR-related protein) stimulating agent, an anti-IDO agent, an anti-ICOS agent, an anti-OX40 agent, an anti-CSF1R agent, a chemokine signaling agent, a cytokine signal stimulating agent, or any combination thereof. In some embodiments, the anti-PD-1 agent is selected from the group consisting of pembrolizumab, nivolumab, PDR001, REGN2810 (SAR-439684), BGB-A317, BI 754091, IBI308, INCSHR-1210, JNJ-63723283, JS-001, MEDI0680 (AMP-514), MGA-012, PF-06801591, REGN-2810, TSR-042, atezolizumab, avelumab, CX-072, durvalumab, FAZ053, LY3300054, PD-L1 millamolecule, and any combinations thereof. In some embodiments, the anti-PD-L1 agent is selected from the group consisting of atezolizumab, durvalumab, avelumab, LY3300054, and any combinations thereof. In some embodiments, the GITR stimulating agent is selected from the group consisting of DTA-1, mGITRL, pGITRL, and any combinations thereof. In some embodiments, the anti-CTLA4 agent is selected from the group consisting of ipilimumab, tremelimumab, and a combination thereof. In some embodiments, the third agent is an anti-immunosuppressive agent or immunostimulatory agent selected from the group consisting of a flavonoid (e.g., flavonoid glycoside), lidocaine, lamotrigine, sulfamethoxazole, phenytoin, carbamazepine, sulfamethoxazole, phenytoin, allopurinol, paracetamol, mepivacaine, p-phenylenediamine, ciprofloxacin and moxifloxacin. In some embodiments, the third agent is a

chemotherapeutic agent selected from the group consisting of aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, vinorelbine, and any combinations thereof.

[00180] In some embodiments, provided herein are compositions, wherein the compositions comprise one or more therapeutic agents disclosed herein. The composition can mean a pharmaceutical composition, and is intended to encompass a therapeutic agent (e.g. drug product) comprising niraparib or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof, and the other inert ingredient(s) (pharmaceutically acceptable excipients). Such pharmaceutical compositions are synonymous with “formulation” and “dosage form”. Pharmaceutical composition of the present disclosure include, but is not limited to, granules, tablets (single layered tablets, multilayered tablets, mini tablets, bioadhesive tablets, caplets, matrix tablets, tablet within a tablet, mucoadhesive tablets, modified release tablets, orally disintegrating tablets, pulsatile release tablets, timed release tablets, delayed release, controlled release, extended release and sustained release tablets), capsules (hard and soft or liquid filled soft gelatin capsules), pills, troches, sachets, powders, microcapsules, minitablets, tablets in capsules and microspheres, matrix composition and the like. In some embodiments, the pharmaceutical composition refers to capsules. In some embodiments, the pharmaceutical composition refers to hard gelatin capsules or HPMC based capsules. In some embodiments, the pharmaceutical composition refers to hard gelatin capsules.

Combination Therapies

[00181] As disclosed herein one or more therapeutic agents can be combined to treat a disease or condition. Combination therapy can provide many benefits including synergistic effect. The

benefits of synergistic effect can include reducing the dose of each therapeutic agent in the combination therapy, and/or reducing the side effect associated with higher doses.

[00182] In one aspect, the present disclosure provides a method of treating a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

[00183] In another aspect, the present disclosure provides a method of preventing a tumor cell growth in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

[00184] In a third aspect, the present disclosure provides a method of preventing tumor metastasis in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

[00185] In a fourth aspect, the present disclosure provides a method of inducing an immune response in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

[00186] In a fifth aspect, the present disclosure provides a method of enhancing an immune response in a subject with a disease or condition comprising administering to the subject a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and a second agent, wherein the second agent comprises an angiogenesis inhibitor.

[00187] The PARP inhibitors and angiogenesis inhibitors are disclosed herein, and different combinations of PARP inhibitors and angiogenesis inhibitors can be used in the combination therapy. Exemplary combinations include, but are not limited to, niraparib and bevacizumab, or niraparib and cabozantinib. Niraparib is an orally available and selective poly (ADP-ribose) polymerase (PARP)-1/-2 inhibitor approved for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy. It is currently being developed in ovarian and other cancers as monotherapy or in combination with other anti-cancer therapies. Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody that can block angiogenesis and inhibit vascular endothelial growth factor A (VEGF-A). It is approved as treatment for many cancer types including colorectal cancer, lung cancer, kidney cancer, and ovarian cancer. Cabozantinib (COMETRIQ®) is a small molecule inhibitor of the tyrosine kinase VEGFR2. It also inhibits c-

Met, AXL and RET. Cabozantinib is approved for the treatment of medullary thyroid cancer and kidney cancer.

[00188] In some embodiments, the first agent is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof. In some embodiments, the first agent is a small molecule. In some embodiments, the first agent is selected from the group consisting of: ABT-767, AZD 2461, BGB-290, BGP 15, CEP 8983, CEP 9722, DR 2313, E7016, E7449, fluzoparib (SHR 3162), IMP 4297, INO1001, JPI 289, JPI 547, monoclonal antibody B3-LysPE40 conjugate, MP 124, niraparib (ZEJULA) (MK-4827), NU 1025, NU 1064, NU 1076, NU1085, olaparib (AZD2281), ONO2231, PD 128763, R 503, R554, rucaparib (RUBRACA) (AG-014699, PF-01367338), SBP 101, SC 101914, Simmiparib, talazoparib (BMN-673), veliparib (ABT-888), WW 46, 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol, and salts or derivatives thereof. In some embodiments, the first agent is selected from the group consisting of: niraparib, olaparib, rucaparib, talazoparib, veliparib, and salts or derivatives thereof. In some embodiments, the first agent is niraparib or a pharmaceutically acceptable salt or derivative thereof.

[00189] In some embodiments, the angiogenesis inhibitor reduces the production of a pro-angiogenic factor, inhibits an interaction between a pro-angiogenic factor and a pro-angiogenic receptor, inhibits a function of a pro-angiogenic factor, inhibits a function of a pro-angiogenic factor receptor, reduces of blood flow by disruption of blood vessels, inhibits vessel sprouting, or any combinations thereof. In some embodiments, the pro-angiogenic factor comprises FGF1-14, FGF15/19, FGF18-23, PDGF, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF, VEGFR-1, VEGFR-2, VEGFR-3, angiogenin, angiopoietin-1, angiopoietin-2, Tie-1, Tie-2, MMP, DII4, SEMA3s, ephrins, leptin, chemokines, transforming growth factor- β (TGF- β), or any combination thereof. In some embodiments, the angiogenesis inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof. In some embodiments, the angiogenesis inhibitor is selected from the group consisting

of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor (e.g. peptide troponin I and chondromodulin I), matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, α V β 3 inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta, interferon alpha, soluble KDR and FLT-1 receptors, placental proliferin-related protein, and any combination thereof. In some embodiments, the angiogenesis inhibitor is selected from the group consisting of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor, matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, α V β 3 inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta, interferon alpha, soluble KDR and FLT-1 receptors, placental proliferin-related protein, pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, protamine, heparin, steroids, ascorbic acid ethers, sulfated polysaccharide DS 4152, fumagillin, AGM 12470, neovastat, RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), Flt2-11, CBO-P11, Je-11, V1, and any combination thereof.

[00190] In some embodiments, the angiogenesis inhibitor inhibits a vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) pathway. In some embodiments, the angiogenesis inhibitor inhibits a VEGF family protein and/or a VEGFR family protein. In some embodiments, the VEGF family protein comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF, or any combination thereof. In some embodiments, the VEGFR family protein comprises VEGFR-1, VEGFR-2, VEGFR-3, or any combination thereof. In some embodiments, the angiogenesis inhibitor comprises a VEGF inhibitor, a VEGFR inhibitor, or a combination thereof. In some embodiments, the angiogenesis inhibitor induces homologous recombinant (HR) deficiency. In some embodiments, the angiogenesis inhibitor induces hypoxia. In some

embodiments, the angiogenesis inhibitor induces homologous recombinant (HR) deficiency by hypoxia. In some embodiments, the VEGF inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof. In some embodiments, the VEGF inhibitor is an antibody or a fragment thereof. In some embodiments, the VEGF inhibitor is bevacizumab, ranibizumab, OPT-302, ziv-aflibercept, or any combinations thereof. In some embodiments, the VEGF inhibitor is a small organic or inorganic molecule. In some embodiments, the small organic or inorganic molecule is Flt2-11, CBO-P11, Je-11, V1, or any combination thereof. In some embodiments, the VEGFR inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof. In some embodiments, the VEGFR inhibitor is a tyrosine kinase inhibitor. In some embodiments, the tyrosine kinase inhibitor is pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, or any combination thereof. In some embodiments, the VEGFR inhibitor is an antibody or a fragment thereof. In some embodiments, the VEGFR inhibitor is ramucirumab.

- [00191] In embodiments, a first agent is niraparib, and a second agent is bevacizumab.
- [00192] In embodiments, a first agent is niraparib, and a second agent is cabozantinib.
- [00193] Therapeutic methods of the invention can be combined with additional immunotherapies and therapies. For example, when used for treating cancer, inhibitors of the invention can be used in combination with conventional cancer therapies, such as, e.g., surgery, radiotherapy, chemotherapy or combinations thereof, depending on type of the tumor, patient condition, other health issues, and a variety of factors.
- [00194] In embodiments, a further therapeutic agent is an immune checkpoint inhibitor. In embodiments, a checkpoint inhibitor is an agent capable of inhibiting any of the following: PD-1 (e.g., inhibition via anti-PD-1, anti-PD-L1, or anti-PD-L2 therapies), CTLA-4, TIM-3, TIGIT, LAGs (e.g., LAG-3), CEACAM (e.g., CEACAM-1, -3 and/or -5), VISTA, BTLA, LAIR1, CD160, 2B4, CD80, CD86, B7-H3 (CD276), B7-H4 (VTCN1), HVEM (TNFRSF14 or CD270), KIR, A2aR, MHC class I, MHC class II, GALS, adenosine, TGFR (e.g., TGFR beta), B7-H1,

B7-H4 (VTCN1), OX-40, CD137, CD40, IDO, or CSF-1R. In embodiments, a checkpoint inhibitor is a small molecule, a nucleic acid, a polypeptide (e.g., an antibody), a carbohydrate, a lipid, a metal, or a toxin. In embodiments, a checkpoint inhibitor is an antibody, an antibody conjugate, or an antigen-binding fragment thereof.

[00195] In certain aspects, other therapeutic agents useful for combination therapy with the inhibitors of the present disclosure include an antigen specific immune response enhancer agent selected from the group consisting of an anti- PD-1 agent, an anti- PD-L1 agent, a GITR (glucocorticoid-induced TNFR-related protein) stimulating agent, an anti-CTLA4 agent, an anti-TIM-3 agent, an anti-LAG-3 agent, a chemokine signaling agent, an anti-VEGF agent, a cytokine signal stimulating agent, and combinations thereof.

[00196] In embodiments, an immune checkpoint inhibitor is a PD-1 inhibitor. In embodiments, a PD-1 inhibitor is a small molecule, a nucleic acid, a polypeptide (e.g., an antibody, an antibody conjugate, or an antigen-binding fragment thereof), a carbohydrate, a lipid, a metal, or a toxin. In embodiments, a PD-1 inhibitor is a PD-1 binding agent (e.g., an antibody, an antibody conjugate, or an antigen-binding fragment thereof). In embodiments, a PD-1 binding agent is an antibody, an antibody conjugate, or an antigen-binding fragment thereof. In some embodiments, the anti- PD-1 agent is selected from the group consisting of pembrolizumab, nivolumab, PDR001, REGN2810 (SAR-439684), BGB-A317, BI 754091, IBI308, INC SHR-1210, JNJ-63723283, JS-001, MEDI0680 (AMP-514), MGA-012, PF-06801591, REGN-2810, TSR-042, and combinations thereof. In embodiments, a PD-1 inhibitor is an anti-PD-L1 or anti-PD-L2 agent. In some embodiments, the anti-PD-L1 agent is selected from the group consisting of atezolizumab, durvalumab, avelumab, LY3300054, and combinations thereof. In embodiments, an anti-PD-1 agent is pembrolizumab. In embodiments, an anti-PD-1 agent is nivolumab. In some embodiments, a PD-1 antibody agent is as disclosed in International Patent Application Publication Nos. WO2014/179664, WO 2018/085468, or WO 2018/129559. In further embodiments, a PD-1 antibody agent is administered according to a method disclosed in International Patent Application Publication Nos. WO2014/179664, WO 2018/085468, or WO 2018/129559. In embodiments, an anti-PD-1 agent is TSR-042.

[00197] In embodiments, an immune checkpoint inhibitor is a TIM-3 inhibitor. In embodiments, a TIM-3 inhibitor is a small molecule, a nucleic acid, a polypeptide (e.g., an antibody, an antibody conjugate, or an antigen-binding fragment thereof), a carbohydrate, a lipid, a metal, or a toxin. In embodiments, a TIM-3 inhibitor is a TIM-3 binding agent (e.g., an antibody, an antibody conjugate, or an antigen-binding fragment thereof). In embodiments, a TIM-3 binding agent is an antibody, an antibody conjugate, or an antigen-binding fragment

thereof. In some embodiments, a TIM-3 antibody agent is MBG453, LY3321367, Sym023, TSR-022, or a derivative thereof. In some embodiments, a TIM-3 antibody agent is as disclosed in International Patent Application Publication Nos. WO2016/161270, WO 2018/085469, or WO 2018/129553. In some embodiments, a TIM-3 antibody agent is administered as disclosed in International Patent Application Publication Nos. WO2016/161270, WO 2018/085469, or WO 2018/129553. In some embodiments, a TIM-3 antibody agent is TSR-022.

[00198] In embodiments, an immune checkpoint inhibitor is a LAG-3 inhibitor. In embodiments, an anti-LAG-3 agent is an antibody, an antibody conjugate, or an antigen-binding fragment thereof. In embodiments, an anti-LAG-3 agent is a small molecule, a nucleic acid, a polypeptide (e.g., an antibody), a carbohydrate, a lipid, a metal, or a toxin. In embodiments, an anti-LAG-3 agent is a small molecule. In embodiments, an anti-LAG-3 agent is a LAG-3 binding agent. In embodiments, an anti-LAG-3 agent is an antibody, an antibody conjugate, or an antigen-binding fragment thereof. In embodiments, an anti-LAG-3 agent is IMP321, relatlimab (BMS-986016), BI 754111, GSK2831781 (IMP-731), Novartis LAG525 (IMP701), REGN3767, MK-4280, MGD-013, GSK-2831781, FS-118, XmAb22841, INCAGN-2385, FS-18, ENUM-006, AVA-017, AM-0003, Avacta PD-L1/LAG-3 bispecific affamer, iOnctura anti-LAG-3 antibody, Arcus anti-LAG-3 antibody, or Sym022, or TSR-033. In some embodiments, a LAG-3 antibody agent is as disclosed in International Patent Application Publication WO2016/126858 or in International Patent Application No. PCT/US18/30027. In some embodiments, a LAG-3 antibody agent is administered as disclosed in International Patent Application Publication WO2016/126858 or in International Patent Application No. PCT/US18/30027. In embodiments, a LAG-3 antibody agent is TSR-033.

[00199] In some embodiments, the GITR stimulating agent is selected from the group consisting of DTA-1, mGITRL, pGITRL, and combinations thereof.

[00200] In some embodiments, the anti-CTLA4 agent is selected from the group consisting of ipilimumab, tremelimumab, and combinations thereof.

[00201] In some embodiments, the chemokine signaling agent is selected from the group consisting of CXCL16, a CXCR6 chemokine receptor (CD186) agonist, and combinations thereof.

[00202] In some embodiments, the cytokine signal stimulating agent is an interleukin or an interferon. In some embodiments, the interleukin is selected from the group consisting of IL-2, IL-1, IL-7, IL-15, IL-12, IL-18 and combinations thereof. In some embodiments, the interferon is IFN alpha.

[00203] In some embodiments, the third agent is an antigen specific immune response enhancer agent selected from the group consisting of a flavonoid (e.g., flavonoid glycoside), lidocaine, lamotrigine, sulfamethoxazole, phenytoin, carbamazepine, sulfamethoxazole, phenytoin, allopurinol, paracetamol, mepivacaine, p-phenylenediamine, ciprofloxacin and moxifloxacin.

[00204] In some embodiments, the third agent is a chemotherapeutic agent. Non-limiting examples of chemotherapeutic agents which can be used in combination treatments of the present disclosure include, for example, aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, and vinorelbine.

[00205] These chemotherapeutic agents may be categorized by their mechanism of action into, for example, following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (5-fluorouracil, floxuridine, capecitabine, gemcitabine and cytarabine) and purine analogs, folate antagonists and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine (cladribine)); antiproliferative/antimitotic agents including natural products such as vinca alkaloids (vinblastine, vincristine, and vinorelbine), microtubule disruptors such as taxane (paclitaxel, docetaxel), vincristin, vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide), DNA damaging agents (actinomycin, amsacrine, anthracyclines, bleomycin, busulfan, camptothecin, carboplatin, chlorambucil, cisplatin, cyclophosphamide, cytoxin, dactinomycin, daunorubicin, doxorubicin, epirubicin, hexamethylenelamineoxaliplatin, ipfosamide, melphalan, mechlorethamine, mitomycin, mitoxantrone, nitrosourea, plicamycin, procarbazine, taxol, taxotere, teniposide, triethylenethiophosphoramide and etoposide (VP16)); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines,

mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethylenimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nitrosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes-dacarbazine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); anti-angiogenic compounds (e.g., TNP-470, genistein, bevacizumab) and growth factor inhibitors (e.g., fibroblast growth factor (FGF) inhibitors); angiotensin receptor blocker; nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab); cell cycle inhibitors and differentiation inducers (tretinoin); mTOR inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), amsacrine, camptothecin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin and mitoxantrone, topotecan, irinotecan), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone); growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers and caspase activators; and chromatin disruptors.

[00206] As used herein, a “chemotherapeutic agent” refers to a chemical agent that inhibits the proliferation, growth, life-span and/or metastatic activity of cancer cells. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN® cyclophosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines (e.g., altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolomelamine); acetogenins; delta-9-tetrahydrocannabinol (e.g., dronabinol, MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; a camptothecin (including the synthetic analogue topotecan (HYCAMTIN®), CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin, and 9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); podophyllotoxin;

podophyllinic acid; teniposide; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabacin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine (ELDISINE®, FILDESIN®); dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxanes, e.g., TAXOL® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE™ Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel

(American Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE® docetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine (VELBAN®); platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine (ONCOVIN®); oxaliplatin; leucovorin; vinorelbine (NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; pharmaceutically acceptable salts, acids or derivatives of any of the above; as well as combinations of two or more of the above such as CHOP, an abbreviation for a combined therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin (ELOXATINTM) combined with 5-FU and leucovorin.

[00207] Also included in this definition are “antimetabolite chemotherapeutic agents” that are structurally similar to a metabolite, but cannot be used by the body in a productive manner. Many antimetabolite chemotherapeutic agents interfere with the production of the nucleic acids, RNA and DNA. Examples of antimetabolite chemotherapeutic agents include gemcitabine (GEMZAR®), 5-fluorouracil (5-FU), capecitabine (XELODA™), 6-mercaptopurine, methotrexate, 6-thioguanine, pemetrexed, raltitrexed, arabinosylcytosine ARA-C cytarabine (CYTOSAR-U®), dacarbazine (DTIC-DOMED), azacytosine, deoxycytosine, pyridimidene, fludarabine (FLUDARA®), cladribine, 2-deoxy-D-glucose etc. In some embodiments, an antimetabolite chemotherapeutic agent is gemcitabine. Gemcitabine HCl is sold by Eli Lilly under the trademark GEMZAR®.

[00208] Also included in this definition are “platinum-based chemotherapeutic agents” that comprises an organic compound which contains platinum as an integral part of the molecule. In some embodiments, a chemotherapeutic agent is a platinum agent. In some such embodiments, the platinum agent is selected from cisplatin, carboplatin, oxaliplatin, nedaplatin, triplatin tetranitrate, phenanthriplatin, picoplatin, or satraplatin.

Administration

[00209] The composition or pharmaceutical composition or therapeutic agent disclosed here can be administered into a subject by various methods. Those of ordinary skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human subject. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.),

enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e.g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and/or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time. For further examples, the pharmaceutical composition can be formulated for administration via pH-dependent release delivery, microbially-triggered delivery, time-controlled delivery, osmotically-regulated delivery, pressure-controlled delivery, multi matrix systems delivery, bioadhesion delivery, or multiparticulate delivery.

[00210] Pharmaceutical compositions of the present disclosure include, but are not limited to, granules, tablets (single layered tablets, multilayered tablets, mini tablets, bioadhesive tablets, caplets, matrix tablets, tablet within a tablet, mucoadhesive tablets, modified release tablets, orally disintegrating tablets, pulsatile release tablets, timed release tablets, delayed release, controlled release, extended release and sustained release tablets), capsules (hard and soft or liquid filled soft gelatin capsules), pills, troches, sachets, powders, microcapsules, minitablets, tablets in capsules and microspheres, matrix composition and the like. In some embodiments, the pharmaceutical composition refers to capsules. In some embodiments, the pharmaceutical composition refers to hard gelatin capsules or HPMC based capsules. In some embodiments, the pharmaceutical composition refers to hard gelatin capsules.

[00211] In some embodiments, a given therapeutic agent is administered according to a regimen, which may involve one or more doses. In some embodiments, a regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some embodiments, a regimen comprises a plurality of doses, wherein the doses are separated by time periods of different length. In some embodiments, a regimen comprises doses of the same amount. In some embodiments, a regimen comprises doses of different amounts. In some embodiments, a regimen comprises at least one dose, wherein the dose comprises one unit dose of the therapeutic agent. In some embodiments, a regimen comprises at least one dose, wherein the dose comprises two or more unit doses of the therapeutic agent.

[00212] In various embodiments, the methods provided herein comprise administering a first agent and a second agent. A first agent and a second agent can be administered in any order. In some embodiments, administering comprises administering the first and second agent

sequentially. In some embodiments, administering comprises administering the first and second agent simultaneously. In some embodiments, administering comprises administering the first agent before administering the second agent. In some embodiments, administering comprises administering the second agent before administering the first agent.

[00213] In some embodiments, the pharmaceutical composition is administered to a subject and the administering comprises administering a composition comprising a capsule, wherein the capsule comprises the first agent. In some embodiments, the capsule comprises a formulation comprising the first agent and one or more pharmaceutically acceptable excipients. In some embodiments, the one or more pharmaceutically acceptable excipients comprise lactose monohydrate, magnesium stearate, or a combination thereof. In some embodiments, a therapeutically effective amount of the first or second agent is administered. In some embodiments, the method further comprises administering a third agent to the subject. In some embodiments, the third agent comprises an antigen specific immune response enhancer agent, a chemotherapeutic agent, or a combination thereof. In some embodiments, the antigen specific immune response enhancer agent comprises an anti- PD-1 agent, an anti- PD-L1 agent, an anti-CTLA4 agent, an anti-TIM-3 agent, or an anti-LAG-3 agent.

Dosing Protocols

[00214] As described herein, provided methods comprise administering a therapy that inhibits PARP and a therapy that regulates activity in the tumor microenvironment (e.g., inhibition of angiogenesis) in combination to a patient, a subject, or a population of subjects according to a regimen that achieves a therapeutic effect.

[00215] In some embodiments, administration “in combination” includes administration of one or more doses of an agent that inhibits PARP (e.g., niraparib) before, during, or after administration of one or more doses of an agent that enhances activity in the tumor microenvironment. In some embodiments, an agent that inhibits PARP (e.g., niraparib) and an agent that regulates activity in the tumor microenvironment are administered in overlapping regimens. In some embodiments, an agent that inhibits PARP (e.g., niraparib) is administered simultaneously or sequentially to an agent that enhances activity in the tumor microenvironment.

[00216] The number of times a composition is administered to an individual in need thereof depends on the discretion of a medical professional, the disorder, the severity of the disorder, and the individual’s response to the formulation. In some embodiments, a composition disclosed herein is administered once to an individual in need thereof with a mild acute condition. In some embodiments, a composition disclosed herein is administered more than once to an individual in need thereof with a moderate or severe acute condition. In the case wherein the patient’s

condition does not improve, upon the doctor's discretion the administration of a combination drug product described herein may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.

[00217] In some embodiments, a therapeutically-effective amount of a therapeutic agent is administered to a subject. The therapeutic agent can be a first, a second, or a third agent. In some embodiments, the therapeutically-effective amount is from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 1 mg/kg/day, from 1 mg/kg/day to about 5 mg/kg/day, from 5 mg/kg/day to about 10 mg/kg/day, from 10 mg/kg/day to about 15 mg/kg/day, from 15 mg/kg/day to about 20 mg/kg/day, from 20 mg/kg/day to about 25 mg/kg/day, from 25 mg/kg/day to about 30 mg/kg/day, from 30 mg/kg/day to about 35 mg/kg/day, or from 35 mg/kg/day to about 40 mg/kg/day. In some embodiments, the therapeutically-effective amount is from 0.1 mg/kg/day to about 40 mg/kg/day. In some embodiments, the therapeutically-effective amount is from 10 mg/kg/day to about 50 mg/kg/day, or from 50 mg/kg/day to about 100 mg/kg/day.

[00218] In some embodiments, a first agent is administered at a dose that is equivalent to about 300 mg of niraparib. In some embodiments, the first agent is administered at a reduced dose. In some embodiments, the reduced dose is equivalent to 200 mg of niraparib. In some embodiments, the reduced dose is equivalent to 100 mg ~ 150 mg, or 150 mg ~200 mg of niraparib. In some embodiments, the first agent (e.g. niraparib) is administered at an increased dose if the subject's hemoglobin \geq 9 g/dL, platelets \geq 100,000/ μ L and neutrophils \geq 1500/ μ L for all labs performed during one or more treatment cycles. In some embodiments, the dose of the first agent (e.g. niraparib) is increased after two cycles of treatment.

Subjects

[00219] In practicing the methods of treatment or use provided herein, therapeutically-effective amounts of the therapeutic agents can be administered to a subject having a disease or condition. A therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.

[00220] Subjects can be, for example, mammals, humans, pregnant women, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, newborn, or neonates. A subject can be a patient. In some cases, a subject can be a human. In some cases, a subject can be a child (*i.e.*, a young human being below the age of puberty). In some cases, a subject can be an infant. In some cases, the subject can be a formula-fed infant. In some cases, a subject can be an

individual enrolled in a clinical study. In some cases, a subject can be a laboratory animal, for example, a mammal, or a rodent. In some cases, the subject can be a mouse. In some cases, the subject can be an obese or overweight subject.

[00221] In some embodiments, the subject has previously been treated with one or more different cancer treatment modalities. In some embodiments, the subject has previously been treated with one or more of radiotherapy, chemotherapy, or immunotherapy. In some embodiments, the subject has been treated with one, two, three, four, or five lines of prior therapy. In some embodiments, the prior therapy is a cytotoxic therapy.

Compositions and Kits

[00222] A composition or pharmaceutical composition of the present disclosure can comprise any of the agents disclosed herein. In some embodiments, the composition or pharmaceutical composition comprises one or more therapeutic agents. The composition or pharmaceutical composition can be administered in combination with another therapy, for example, immunotherapy, chemotherapy, radiotherapy, anti-inflammatory agents, anti-viral agents, anti-microbial agents, and anti-fungal agents.

[00223] A composition or a pharmaceutical composition of the present disclosure can be packaged as a kit. In some embodiments, a kit comprises a pharmaceutical composition disclosed herein. In some embodiments, a kit comprises a first, a second, and/or a third therapeutic agent disclosed herein. In some applications, a kit includes written instructions on the administration/use of the therapeutic composition. The written material can be, for example, a label. The written material can suggest conditions methods of administration. The instructions provide the subject and the supervising physician with the best guidance for achieving the optimal treatment outcome from the administration of the therapy. The written material can be a label. In some applications, the label can be approved by a regulatory agency, for example the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory agencies.

EXAMPLES

[00224] The following examples evaluated antitumor activity of PARP inhibitors in combination with angiogenesis inhibitors. The compounds of these combination therapies serve as examples only, and are not intended to be limiting.

Example 1 – Study design

[00225] In vivo studies were designed in order to test the effect of combination treatments. The study design is summarized in **Table 1**.

Table 1 - *In vivo* study design for combination treatment

Tumor type	Ovarian Cancer		TNBC
Model	A2780	A2780, OVC134	MAXF 574, MAXF 857, MAXF MX1
Mouse Strain	CB-17 SCID female	Balb/C nude female	NMRI nude female
Treatment arms	Vehicle Niraparib (N) Bevacizumab (B) N+B	Vehicle Niraparib (N) Cabozantinib (C) N+C	Vehicle Niraparib (N) Bevacizumab (B) Cabozantinib (C) N+B N+C
Number of mice per arm	6	6	3
Niraparib dosing	60 mg/kg po qd	60 mg/kg po qd	50 mg/kg po qd
Bevacizumab dosing	10 mg/kg iv qw		20 mg/kg iv qw
Cabozantinib dosing		30 mg/kg po qd	30 mg/kg po qd

“po” means “by mouth”, “qd” means “once a day”, “iv” means “intravenous”, and “qw” means “once a week”

Example 2 – Niraparib and bevacizumab combination therapy demonstrated enhanced anti-tumor activity in both ovarian and TNBC models

[00226] As shown in **Figure 1**, one ovarian cancer (OC) model and three triple negative breast cancer (TNBC) models were treated with niraparib, bevacizumab, and their combination. Tumor growth inhibition (TGI) at the end of treatment was calculated and illustrated. Combination benefit (TGI for N+B at least 10% higher than either monotherapy) was observed in OC model A2780 and TNBC model MAXF 574. Combination benefit could not be seen in the other two TNBC models MAXF 857 and MAXF MX1 because the models are sensitive to bevacizumab monotherapy (TGI: 76%) and niraparib monotherapy (TGI: 99%), respectively.

Example 3 – Niraparib and cabozantinib combination therapy demonstrated enhanced anti-tumor activity in both ovarian and TNBC models

[00227] As shown in **Figure 2**, two ovarian cancer models and three TNBC models were treated with niraparib, cabozantinib, and their combinations. Tumor growth inhibition at the end of treatment was calculated and illustrated. Combination benefit (TGI for N+C at least 10% higher than either monotherapy) was observed in OC model A2780 and TNBC model MAXF 574. Combination benefit could not be seen in the other three models because OVC134 and MAXF 857 are sensitive to cabozantinib monotherapy (TGI: 83% and 65% respectively), and MAXF MX1 is sensitive to niraparib monotherapy (TGI: 99%).

Example 4 – Results of tolerability and antitumor activity of niraparib and bevacizumab combination in ovarian cancer cell line-derived xenograft model A2780 (BRCA wt, HRD-)

[00228] As shown in **Figures 3A and 3B**, tumor bearing mice were randomized into 4 cohorts and treated with vehicle, niraparib, cabozantinib, and niraparib + cabozantinib for 2 weeks. Tumor size and body weight were measured twice weekly. Both monotherapies and the combination are well tolerated without significant body weight loss. In this BRCA wild type and HRD negative model, combination of niraparib and bevacizumab demonstrated enhanced anti-tumor activity (TGI=68%) compared with niraparib monotherapy (TGI <40%) and bevacizumab monotherapy (TGI=55%).

Example 5 – Results of tolerability and antitumor activity of niraparib and cabozantinib combination in ovarian cancer cell line-derived xenograft model A2780 (BRCA wt, HRD-)

[00229] As shown in **Figures 4A and 4B**, tumor bearing mice were randomized into 4 cohorts and treated with vehicle, niraparib, cabozantinib, and niraparib + cabozantinib combination for 2 weeks. Tumor size and body weight were measured twice weekly. Both monotherapies and the combination are well tolerated with no significant body weight loss. In this BRCA wild type and HRD negative model, combination of niraparib and cabozantinib demonstrated enhanced anti-tumor activity (TGI=78%) compared with niraparib monotherapy (TGI 18%) and cabozantinib monotherapy (TGI=51%).

Example 6 – Results of anti-tumor activity of niraparib and cabozantinib combination in ovarian PDX model OVC134

[00230] As shown in **Figure 5**, tumor bearing mice were randomized into 4 cohorts and treated with vehicle, niraparib, cabozantinib, and niraparib + cabozantinib combination for 7 weeks. Tumor size and body weight were measured twice weekly. This model is very sensitive to both niraparib and cabozantinib monotherapy, therefore no additional combination benefit could be observed for the combination.

Example 7 – Results of anti-tumor activity of niraparib + bevacizumab combination and niraparib + cabozantinib combination in TNBC PDX model MAXF 574

[00231] As shown in **Figures 6A and 6B**, tumor bearing mice were randomized into 6 cohorts and treated with vehicle, niraparib, bevacizumab, niraparib + bevacizumab combination, cabozantinib, and niraparib + cabozantinib combination for 5 weeks. Tumor size and body weight were measured twice weekly. Combination benefit was observed for both niraparib + bevacizumab and niraparib + cabozantinib combinations.

Example 8 – Results of anti-tumor activity of niraparib + bevacizumab combination and niraparib + cabozantinib combination in TNBC PDX model MAXF 857

[00232] As shown in **Figures 7A** and **7B**, tumor bearing mice were randomized into 6 cohorts and treated with vehicle, niraparib, bevacizumab, niraparib + bevacizumab, cabozantinib, niraparib + cabozantinib for 5 weeks. Tumor size and body weight were measured twice weekly. Niraparib + bevacizumab combination and niraparib + cabozantinib combination are presented in 2 separated grafts for better viewing. This model is very sensitive to both bevacizumab and cabozantinib monotherapy, therefore no additional combination benefit could be observed for either niraparib + bevacizumab or niraparib + cabozantinib combination.

Example 9 – Results of anti-tumor activity of niraparib + bevacizumab combination and niraparib + cabozantinib combination in TNBC PDX model MAXF MX1

[00233] As shown in **Figure 8A** and **8B**, TNBC model MAXF MX1 tumor bearing mice were randomized into 6 cohorts and treated with vehicle, niraparib, bevacizumab, niraparib + bevacizumab, cabozantinib, niraparib + cabozantinib for 5 weeks. Tumor size and body weight were measured twice weekly. This model is very sensitive to niraparib monotherapy, therefore no further combination benefit could be observed for either niraparib + bevacizumab or niraparib + cabozantinib.

[00234] While various embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

WHAT IS CLAIMED IS:

1. A method of treating a subject with a disease or condition comprising administering to the subject
 - (a) a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and
 - (b) a second agent, wherein the second agent comprises an angiogenesis inhibitor.
2. A method of preventing a tumor cell growth in a subject with a disease or condition comprising administering to the subject
 - (a) a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and
 - (b) a second agent, wherein the second agent comprises an angiogenesis inhibitor.
3. A method of preventing tumor metastasis in a subject with a disease or condition comprising administering to the subject
 - (a) a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and
 - (b) a second agent, wherein the second agent comprises an angiogenesis inhibitor.
4. A method of inducing an immune response in a subject with a disease or condition comprising administering to the subject
 - (a) a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and
 - (b) a second agent, wherein the second agent comprises an angiogenesis inhibitor.
5. A method of enhancing an immune response in a subject with a disease or condition comprising administering to the subject
 - (a) a first agent that inhibits poly [ADP-ribose] polymerase (PARP); and
 - (b) a second agent, wherein the second agent comprises an angiogenesis inhibitor.
6. The method of any one of claims 1-5, wherein the first agent inhibits PARP1, or PARP2, or both.
7. The method of any one of claims 1-6, wherein the first agent is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof.

8. The method of any one of claims 1-7, wherein the first agent is a small molecule.
9. The method of any one of claims 1-8, wherein the first agent is selected from the group consisting of: ABT-767, AZD 2461, BGB-290, BGP 15, CEP 8983, CEP 9722, DR 2313, E7016, E7449, fluzoparib (SHR 3162), IMP 4297, INO1001, JPI 289, JPI 547, monoclonal antibody B3-LysPE40 conjugate, MP 124, niraparib (ZEJULA) (MK-4827), NU 1025, NU 1064, NU 1076, NU1085, olaparib (AZD2281), ONO2231, PD 128763, R 503, R554, rucaparib (RUBRACA) (AG-014699, PF-01367338), SBP 101, SC 101914, Simmiparib, talazoparib (BMN-673), veliparib (ABT-888), WW 46, 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol, and salts or derivatives thereof.
10. The method of any one of claims 1-9, wherein the first agent is selected from the group consisting of: niraparib, olaparib, rucaparib, talazoparib, veliparib, and salts or derivatives thereof.
11. The method of any one of claims 1-10, wherein the first agent is niraparib or a pharmaceutically acceptable salt or derivative thereof.
12. The method of any one of claims 1-11, wherein the angiogenesis inhibitor reduces the production of a pro-angiogenic factor, inhibits an interaction between a pro-angiogenic factor and a pro-angiogenic receptor, inhibits a function of a pro-angiogenic factor, inhibits a function of a pro-angiogenic factor receptor, reduces of blood flow by disruption of blood vessels, inhibits vessel sprouting, or any combinations thereof.
13. The method of claim 12, wherein the pro-angiogenic factor comprises a fibroblast growth factor (FGF) family protein, FGF1-14, FGF15/19, FGF18-23, PDGF, a vascular endothelial growth factor (VEGF) family protein, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF, VEGFR-1, VEGFR-2, VEGFR-3, angiogenin, angiopoietin-1, angiopoietin-2, Tie-1, Tie-2, MMP, DII4, SEMA3s, ephrins, leptin, chemokines, a transforming growth factor (TGF) family protein, transforming growth factor- β (TGF- β), or any combination thereof.
14. The method of any one of claims 1-13, wherein the angiogenesis inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative;

an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof.

15. The method of any one of claims 1-14, wherein the angiogenesis inhibitor is selected from the group consisting of bevacizumab, itraconazole, carboxyamidotriazole, TNP-470, fumagillin, CM101, IL-12, platelet factor-4, suramin, SU5416, thrombospondin, angiostatic steroids, heparin, cartilage-derived angiogenesis inhibitory factor, matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thrombospondin, thalidomide, prolactin, α V β 3 inhibitor, lenalidomide, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib, sunitinib, pazopanib, everolimus, tissue inhibitors of metalloproteinases (TIMP1 and TIMP2), bFGF soluble receptor, transforming growth factor beta, interferon alpha, soluble KDR and FLT-1 receptors, placental proliferin-related protein, pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, protamine, heparin, steroids, ascorbic acid ethers, sulfated polysaccharide DS 4152, fumagillin, AGM 12470, neovastat, RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), Flt₂₋₁₁, CBO-P11, Je-11, V1, and any combination thereof.
16. The method of any one of claims 1-14, wherein the angiogenesis inhibitor inhibits a DLL4/Notch signaling pathway.
17. The method of claim 16, wherein the angiogenesis inhibitor inhibiting the DLL4/Notch signaling pathway is a gamma-secretase inhibitor (GSI), a siRNA, or a monoclonal antibody against a Notch receptor or ligand.
18. The method of claim 16 or 17, wherein the angiogenesis inhibitor inhibiting a DLL4/Notch signaling pathway is selected from the group consisting of RO4929097, MRK-003, MK-0752, PF03084014, MEDI0639, curcumin, 3,3'-diindolylmethane (DIM), resveratrol, 3,5-bis(2,4-difluorobenzylidene)-4-piperidone (DiFiD) and epigallocatechin-3-gallate (EGCG), honokiol, OMP-21M18, navicixizumab (OMP-305B83), and any combination thereof.

19. The method of any one of claims 1-14, wherein the angiogenesis inhibitor inhibits a vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) pathway.
20. The method of claim 19, wherein the angiogenesis inhibitor is selected from the group consisting of Akt inhibitor, calcineurin autoinhibitory peptide, ET-18-OCH₃, Go 6983, N^G-Nitro-L-arginine methyl ester, p21-activated kinase Inhibitor, cPLA2 α inhibitor, PI-103, PP2, SB 203580, U0126, VEGFR tyrosine kinase inhibitor V, VEGFR2 kinase inhibitor VI, VEGFR2 kinase inhibitor III, ZM 336372, and any combination thereof.
21. The method of claim 19 or 20, wherein the angiogenesis inhibitor inhibits a VEGF family protein and/or a VEGFR family protein.
22. The method of claim 21, wherein the VEGF family protein comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF (placental growth factor), VEGF-E (Orf-VEGF), *Trimeresurus flavoviridis* svVEGF, or any combination thereof.
23. The method of claim 21 or 22, wherein the VEGFR family protein comprises VEGFR-1, VEGFR-2, VEGFR-3, or any combination thereof.
24. The method of any one of claims 19-23, wherein the angiogenesis inhibitor comprises a VEGF inhibitor, a VEGFR inhibitor, or a combination thereof.
25. The method of any one of claims 1-24, wherein the angiogenesis inhibitor induces homologous recombinant (HR) deficiency.
26. The method of any one of claims 1-25, wherein the angiogenesis inhibitor induces hypoxia.
27. The method of any one of claims 1-26, wherein the angiogenesis inhibitor induces homologous recombinant (HR) deficiency by hypoxia.
28. The method of any one of claims 24-27, wherein the VEGF inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; or any combination thereof.


29. The method of claim 28, wherein the VEGF inhibitor is an antibody or a fragment thereof.
30. The method of claim 29, wherein the VEGF inhibitor is bevacizumab, ranibizumab, OPT-302, ziv-aflibercept, or any combinations thereof.
31. The method of claim 28, wherein the VEGF inhibitor is a small organic or inorganic molecule.
32. The method of claim 31, wherein the small organic or inorganic molecule is Flt2-11, CBO-P11, Je-11, V1, or any combination thereof.
33. The method of any one of claims 24-32, wherein the VEGFR inhibitor is a small organic or inorganic molecule; a saccharine; an oligosaccharide; a polysaccharide; a carbohydrate; a peptide; a protein; a peptide analog; a peptide derivative; a lipid; an antibody; an antibody fragment, a peptidomimetic; a nucleic acid; a nucleic acid analog; a nucleic acid derivative; an extract made from biological materials; a naturally occurring or synthetic composition; a metal; a toxin; a tyrosine kinase inhibitor; or any combination thereof.
34. The method of any one of claims 24-33, wherein the VEGFR inhibitor is a tyrosine kinase inhibitor.
35. The method of claim 34, wherein the tyrosine kinase inhibitor is pazopanib, sunitinib, sorafenib, axitinib, ponatinib, cabozantinib, regorafenib, vandetanib, lenvatinib, semaxanib, SU6668, vatalanib, tivozanib, cediranib, or any combination thereof.
36. The method of any one of claims 24-34, wherein the VEGFR inhibitor is an antibody or a fragment thereof.
37. The method of claim 36, wherein the VEGFR inhibitor is ramucirumab.
38. The method of any one of claims 1-14, wherein the first agent is niraparib, and the second agent is cabozantinib.
39. The method of any one of claims 1-14, wherein the first agent is niraparib, and the second agent is bevacizumab.
40. The method of any one of claims 1-39, wherein administering comprises administering the first and second agent sequentially.

41. The method of any one of claims 1-39, wherein administering comprises administering the first and second agent simultaneously.
42. The method of any one of claims 1-39, wherein administering comprises administering the first agent before administering the second agent.
43. The method of any one of claims 1-39, wherein administering comprises administering the second agent before administering the first agent.
44. The method of any one of claims 1-43, wherein the subject is a mammalian subject.
45. The method of any one of claims 1-44, wherein the subject is a mouse.
46. The method of any one of claims 1-44, wherein the subject is a human.
47. The method of any one of claims 1-46, wherein the disease or condition is cancer.
48. The method of claim 47, wherein the cancer is selected from the group consisting of carcinoma, squamous carcinoma, adenocarcinoma, sarcomata, endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal cancer, colon cancer, colorectal cancer, squamous cell carcinoma of the anogenital region, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, squamous cell carcinoma of the lung, stomach cancer, bladder cancer, gall bladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, glioblastoma, glioma, squamous cell carcinoma of the head and neck, prostate cancer, pancreatic cancer, mesothelioma, sarcoma, hematological cancer, leukemia, lymphoma, neuroma, and combinations thereof.
49. The method of claim 48, wherein the cancer is breast cancer.
50. The method of claim 49, wherein the breast cancer is triple negative breast cancer.
51. The method of claim 48, wherein the cancer is ovarian cancer.
52. The method of claim 48, wherein the cancer is colorectal cancer.
53. The method of any one of claims 47-52, wherein the first agent is niraparib, and the second agent is bevacizumab.

54. The method of any one of claims 47-52, wherein the first agent is niraparib, and the second agent is cabozantinib.
55. The method of any one of claims 1-54, wherein administering the first agent, the second agent, or both comprises administering the first agent, the second agent, or both ocularly, oral, parenterally, topically, bronchially, buccally, intradermally, interdermally, transdermally, enterally, intra-arterially, intradermally, intragastrically, intramedullarily, intramuscular, intranasally, intraperitoneally, intrathecally, intravenously, intraventricular, within a specific organ (e.g., intrahepatically), mucosally, nasally, orally, rectally, subcutaneously, sublingually, topically, tracheally, vaginally, vitreally, or any combination thereof.
56. The method of any one of claims 1-55, wherein administering comprises administering a composition formulated for oral administration comprising the first agent.
57. The method of claim 56, wherein the composition is a capsule.
58. The method of claim 56, wherein the composition is a tablet.
59. The method of any one of claims 56-58, wherein the composition further comprises one or more pharmaceutically acceptable excipients.
60. The method of claim 59, wherein the one or more pharmaceutically acceptable excipients comprises lactose monohydrate, magnesium stearate, or a combination thereof.
61. The method of any one of claims 1-60, wherein a therapeutically effective amount of the first or second agent is administered.
62. The method of any one of claims 1-61, wherein the subject has previously been treated with one or more different cancer treatment modalities.
63. The method of claim 62, wherein the subject has previously been treated with one or more of radiotherapy, chemotherapy, or immunotherapy.
64. The method of claim 62 or 63, wherein the subject has been treated with one, two, three, four, or five lines of prior therapy.
65. The method of any one of claims 62-64, wherein the prior therapy is a cytotoxic therapy.

66. The method of any one of claims 1-65, wherein the method further comprises administering a third agent to the subject, or performing a therapy on the subject selected from the group consisting of surgery, radiotherapy, or a combination thereof.
67. The method of claim 66, wherein the third agent comprises a radiotherapeutic agent, an anti-immunosuppressive agent or immunostimulatory agent, a chemotherapeutic agent, or a combination thereof.
68. The method of claim 67, wherein the anti-immunosuppressive agent or immunostimulatory agent comprises an anti-PD-1 agent, an anti-PD-L1 agent, an anti-CTLA4 agent, an anti-TIM-3 agent, an anti-LAG-3 agent, a GITR (glucocorticoid-induced TNFR-related protein) stimulating agent, an anti-IDO agent, an anti-ICOS agent, an anti-OX40 agent, an anti-CSF1R agent, a chemokine signaling agent, a cytokine signal stimulating agent, or any combination thereof.
69. The method of claim 68, wherein the anti-PD-1 agent is selected from the group consisting of pembrolizumab, nivolumab, PDR001, REGN2810 (SAR-439684), BGB-A317, BI 754091, IBI308, INC038-1210, JNJ-63723283, JS-001, MEDI0680 (AMP-514), MGA-012, PF-06801591, REGN-2810, TSR-042, atezolizumab, avelumab, CX-072, durvalumab, FAZ053, LY3300054, PD-L1 millamolecule, and any combinations thereof.
70. The method of claim 68 or 69, wherein the anti-PD-L1 agent is selected from the group consisting of atezolizumab, durvalumab, avelumab, LY3300054, and any combinations thereof.
71. The method of any one of claims 68-70, wherein the GITR stimulating agent is selected from the group consisting of DTA-1, mGITRL, pGITRL, and any combinations thereof.
72. The method of any one of claims 68-71, wherein the anti-CTLA4 agent is selected from the group consisting of ipilimumab, tremelimumab, and a combination thereof.
73. The method of any one of claims 67-72, wherein the third agent is an anti-immunosuppressive agent or immunostimulatory agent selected from the group consisting of a flavonoid (e.g., flavonoid glycoside), lidocaine, lamotrigine, sulfamethoxazole, phenytoin, carbamazepine, sulfamethoxazole, phenytoin, allopurinol, paracetamol, mepivacaine, p-phenylenediamine, ciprofloxacin and moxifloxacin.

74. The method of any one of claims 67-73, wherein the third agent is a chemotherapeutic agent selected from the group consisting of aminoglutethimide, amsacrine, anastrozole, asparaginase, bcg, bicalutamide, bleomycin, buserelin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clodronate, colchicine, cyclophosphamide, cyproterone, cytarabine, dacarbazine, dactinomycin, daunorubicin, dienestrol, diethylstilbestrol, docetaxel, doxorubicin, epirubicin, estradiol, estramustine, etoposide, exemestane, filgrastim, fludarabine, fludrocortisone, fluorouracil, fluoxymesterone, flutamide, gemcitabine, genistein, goserelin, hydroxyurea, idarubicin, ifosfamide, imatinib, interferon, irinotecan, ironotecan, letrozole, leucovorin, leuprolide, levamisole, lomustine, mechlorethamine, medroxyprogesterone, megestrol, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitotane, mitoxantrone, nilutamide, nocodazole, octreotide, oxaliplatin, paclitaxel, pamidronate, pentostatin, plicamycin, porfimer, procarbazine, raltitrexed, rituximab, streptozocin, suramin, tamoxifen, temozolomide, teniposide, testosterone, thioguanine, thiotepa, titanocene dichloride, topotecan, trastuzumab, tretinoin, vinblastine, vincristine, vindesine, vinorelbine, and any combinations thereof.
75. A pharmaceutical composition comprising the first and second agent of any one of claims 1-74.
76. The pharmaceutical composition of claim 75, further comprising the third agent of claims 66-74.
77. A kit comprising the first and the second agent of any one of claims 1-74.
78. The kit of claim 77, further comprising the third agent of claims 66-74.

**FIGURE 1**

2/13




FIGURE 2

3/13




FIGURE 3A

4/13




FIGURE 3B

5/13




FIGURE 4A

6/13




FIGURE 4B

7/13






FIGURE 5


8/13

**FIGURE 6A**


9/13

**FIGURE 6B**


10/13

**FIGURE 7A**

11/13

**FIGURE 7B**

12/13

MAXF MX1: Niraparib+Bevacizumab**FIGURE 8A**

13/13

MAXF MX1: Niraparib+Cabozantinib




FIGURE 8B

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2018/054606

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K45/00 A61P35/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2017/142871 A1 (ASTRAZENECA AB [SE]; NAT INST HEALTH [US]) 24 August 2017 (2017-08-24) page 11, paragraph 2; claims 1, 10-12; example 6 ----- US 2009/123419 A1 (SHERMAN BARRY M [US] ET AL) 14 May 2009 (2009-05-14) paragraph [0105]; claims 18, 19 ----- WO 2009/064738 A2 (BIPAR SCIENCES INC [US]; SHERMAN BARRY [US]; BRADLEY CHARLES [US]; OSS) 22 May 2009 (2009-05-22) paragraphs [0008] - [0083] -----	1-3, 6-42, 44-56, 67-75,77 1-3,6-78 1-3,7-78
X		



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

22 January 2019

28/03/2019

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Cattell, James

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2018/054606

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

2, 3(completely); 1, 6-78(partially)

Remark on Protest

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 2, 3(completely); 1, 6-78(partially)

Methods of treating tumour cell growth

2. claims: 4, 5(completely); 1, 6-78(partially)

Methods of inducing or enhancing an immune response

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2018/054606

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2017142871	A1	24-08-2017	AU	2017221268 A1		30-08-2018
			CA	3014674 A1		24-08-2017
			CN	109073650 A		21-12-2018
			EP	3417294 A1		26-12-2018
			JP	2019504860 A		21-02-2019
			KR	20180125456 A		23-11-2018
			WO	2017142871 A1		24-08-2017
<hr/>						
US 2009123419	A1	14-05-2009	AU	2008321382 A1		22-05-2009
			CA	2705417 A1		22-05-2009
			CN	101918003 A		15-12-2010
			CO	6290649 A2		20-06-2011
			CR	11486 A		09-08-2013
			DO	P2010000142 A		31-07-2010
			DO	P2012000290 A		31-03-2013
			EC	SP10010235 A		30-07-2010
			EP	2217244 A2		18-08-2010
			GT	201000137 A		23-04-2012
			JP	2011503071 A		27-01-2011
			KR	20100102607 A		24-09-2010
			MA	32748 B1		01-11-2011
			NZ	586123 A		21-12-2012
			SG	185954 A1		28-12-2012
			TN	2010000209 A1		11-11-2011
			US	2009123419 A1		14-05-2009
			US	2010009930 A1		14-01-2010
			WO	2009064444 A2		22-05-2009
<hr/>						
WO 2009064738	A2	22-05-2009	AR	069291 A1		13-01-2010
			AU	2008321128 A1		22-05-2009
			CA	2705537 A1		22-05-2009
			CN	101917982 A		15-12-2010
			CN	103169973 A		26-06-2013
			CO	6290650 A2		20-06-2011
			CR	11485 A		13-09-2010
			DO	P2010000141 A		31-07-2010
			DO	P2012000291 A		15-04-2013
			EC	SP10010240 A		30-07-2010
			EP	2217227 A2		18-08-2010
			GT	201000140 A		23-04-2012
			JP	2011503111 A		27-01-2011
			KR	20100102609 A		24-09-2010
			MA	31909 B1		01-12-2010
			NZ	586125 A		21-12-2012
			RU	2010123884 A		20-12-2011
			RU	2012153963 A		20-06-2014
			SG	185952 A1		28-12-2012
			TN	2010000208 A1		11-11-2011
			TW	200924739 A		16-06-2009
			TW	201249430 A		16-12-2012
			US	2009131529 A1		21-05-2009
			US	2010003192 A1		07-01-2010
			US	2012269861 A1		25-10-2012
			WO	2009064738 A2		22-05-2009
<hr/>						